{
  "as_of_date": "October 14, 2025",
  "programs": [
    {
      "asset": "AKEEGA (niraparib/abiraterone)",
      "indication": "M1 Metastatic Castration-Sensitive Prostate Cancer",
      "phase": null,
      "trial_or_program": "AMPLITUDE",
      "partner": "TESARO, an oncology-focused business within GSK",
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT06392841",
          "title": "Hispanic/Latino and Non-Hispanic BlAck Patients Treated With niRaparib and Abiraterone Acetate Plus Prednisone for Metastatic hOrmone Sensitive Prostate Cancer With Deleterious Homologous recombinatioN Repair Alterations: a Phase II, Open Label studY",
          "overall_status": "WITHDRAWN",
          "phase": "Phase 2",
          "conditions": [
            "Metastatic Hormone-sensitive Prostate Cancer (mHSPC)",
            "Deleterious HRR Gene Mutation",
            "BRCA1 Gene Mutation",
            "BRCA2 Gene Mutation",
            "BRIP1 Gene Mutation",
            "CHEK2 Gene Mutation",
            "FANCA Gene Mutation",
            "PALB2 Gene Mutation",
            "RAD51B Gene Mutation",
            "RAD54L Gene Mutation"
          ],
          "lead_sponsor": "Qian Qin",
          "collaborators": [
            "UT Southwestern Comprehensive Cancer Center",
            "Janssen, LP"
          ],
          "interventions": [
            "Androgen Deprivation Therapy (ADT)",
            "Niraparib/Abiraterone Acetate DAT",
            "Abiraterone Acetate",
            "Prednisone",
            "Docetaxel"
          ],
          "last_update": "2025-10-20",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06392841"
        },
        {
          "nct_id": "NCT06212583",
          "title": "A Randomized Trial of High-risK metachroNous oligometastatIc Prostate Cancer With hiGh-risk Mutations Treated witH meTastasiS Directed Therapy and Niraparib/Abiraterone Acetate and Prednisone (KNIGHTS)",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Prostate Cancer",
            "Oligometastatic Disease"
          ],
          "lead_sponsor": "University of Maryland, Baltimore",
          "collaborators": [
            "Janssen Scientific Affairs, LLC"
          ],
          "interventions": [
            "niraparib/abiraterone acetate",
            "Stereotactic ablative radiation therapy (SABR)",
            "Androgen deprivation therapy (ADT)"
          ],
          "last_update": "2025-05-01",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06212583"
        },
        {
          "nct_id": "NCT05689021",
          "title": "Phase 2 Study of CJNJ-67652000 (Niraparib/Abiraterone Acetate Fixed-Dose Combination) and Prednisone for Metastatic Castration-Resistant Prostate Cancer Associated With SPOP Mutation With or Without Homologous Recombination Deficiency",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Castration-Resistant Prostate Carcinoma",
            "Metastatic Prostate Adenocarcinoma",
            "Stage IVB Prostate Cancer AJCC v8"
          ],
          "lead_sponsor": "Mayo Clinic",
          "collaborators": [],
          "interventions": [
            "Abiraterone Acetate/Niraparib",
            "Biospecimen Collection",
            "Bone Scan",
            "Computed Tomography",
            "Magnetic Resonance Imaging",
            "Prednisone"
          ],
          "last_update": "2026-01-07",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05689021"
        },
        {
          "nct_id": "NCT04577833",
          "title": "An Open-label, Randomized Study to Assess the Relative Bioavailability (BA) and Bioequivalence (BE) of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Prostatic Neoplasms"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Niraparib",
            "Abiraterone Acetate (AA)",
            "Prednisone"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04577833"
        },
        {
          "nct_id": "NCT03431350",
          "title": "A Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Prostatic Neoplasms, Castration-Resistant"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Niraparib 200 mg",
            "Cetrelimab 240 mg",
            "Cetrelimab 480 mg",
            "Abiraterone acetate 1000 mg",
            "Prednisone 5 mg"
          ],
          "last_update": "2025-12-23",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT03431350"
        },
        {
          "nct_id": "NCT04497844",
          "title": "A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Metastatic Castration-sensitive Prostate Cancer"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Niraparib",
            "Abiraterone acetate (AA)",
            "Prednisone",
            "Placebo for Niraparib"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04497844"
        },
        {
          "nct_id": "NCT03748641",
          "title": "A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Metastatic Prostate Cancer",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Castration-Resistant Prostatic Cancer"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Niraparib",
            "Abiraterone Acetate",
            "Prednisone",
            "Placebo",
            "New Formulation of Niraparib and Abiraterone Acetate (AA)"
          ],
          "last_update": "2025-12-22",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT03748641"
        },
        {
          "nct_id": "NCT06329830",
          "title": "Safety and Anti-tumor Activity of Lutetium-177 (177Lu)-PSMA-617 Along With Niraparib and Abiraterone Acetate Plus Prednisone in Metastatic Castration Resistant Prostate Cancer - LUNAAR Study",
          "overall_status": "WITHDRAWN",
          "phase": "Phase 2",
          "conditions": [
            "Metastatic Prostate Cancer",
            "Castration-resistant Prostate Cancer",
            "Metastatic Castration-resistant Prostate Cancer"
          ],
          "lead_sponsor": "Baptist Health South Florida",
          "collaborators": [
            "Janssen Scientific Affairs, LLC"
          ],
          "interventions": [
            "177Lu-PSMA-617",
            "Niraparib abiraterone acetate",
            "Prednisone"
          ],
          "last_update": "2024-09-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06329830"
        },
        {
          "nct_id": "NCT03903835",
          "title": "ProBio: An Outcome-adaptive and Randomized Multi-arm Biomarker Driven Study in Patients With Metastatic Prostate Cancer",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Metastatic Castration-resistant Prostate Cancer (mCRPC)",
            "Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)"
          ],
          "lead_sponsor": "Karolinska Institutet",
          "collaborators": [
            "The Swedish Research Council",
            "Kom Op Tegen Kanker",
            "Janssen Pharmaceutica N.V., Belgium",
            "AstraZeneca",
            "Cancerfonden"
          ],
          "interventions": [
            "Enzalutamide Oral Capsule",
            "Abiraterone Oral Tablet",
            "Carboplatin",
            "Cabazitaxel 60 mg Solution for Injection",
            "Docetaxel Injectable Solution",
            "Radium Chloride Ra-223",
            "Niraparib plus Abiraterone acetate plus Prednisone",
            "Capivasertib plus Docetaxel",
            "Apalutamide",
            "Darolutamide"
          ],
          "last_update": "2025-04-09",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT03903835"
        },
        {
          "nct_id": "NCT04812366",
          "title": "Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Prostate Cancer"
          ],
          "lead_sponsor": "University of British Columbia",
          "collaborators": [
            "Janssen Inc.",
            "University Health Network, Toronto"
          ],
          "interventions": [
            "Apalutamide 60mg Tab",
            "Abiraterone Acetate 250mg",
            "Prednisone 5mg Tab",
            "Docetaxel",
            "Niraparib 100mg Oral Capsule",
            "Atezolizumab"
          ],
          "last_update": "2024-12-16",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04812366"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok",
      "_ctgov_query_terms": [
        "AKEEGA (niraparib/abiraterone)",
        "niraparib/abiraterone",
        "AKEEGA (niraparib",
        "abiraterone)"
      ]
    },
    {
      "asset": "DARZALEX (daratumumab)",
      "indication": "Smoldering Multiple Myeloma",
      "phase": null,
      "trial_or_program": "AQUILA",
      "partner": "Genmab A/S",
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT03500445",
          "title": "Open-label, Single-arm, Phase 2 Study of Initial Treatment With Daratumumab (Darzalex), Carfilzomib (Kyprolis), Lenalidomide (Revlimid) and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma Requiring Systemic Chemotherapy",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Myeloma",
            "Multiple Myeloma"
          ],
          "lead_sponsor": "University of Chicago",
          "collaborators": [
            "Janssen Scientific Affairs, LLC",
            "Amgen"
          ],
          "interventions": [
            "Daratumumab",
            "Carfilzomib",
            "Lenalidomide",
            "Dexamethasone"
          ],
          "last_update": "2025-10-03",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT03500445"
        },
        {
          "nct_id": "NCT03289299",
          "title": "Aggressive Smoldering Curative Approach Evaluating Novel Therapies (ASCENT): A Phase 2 Trial of Induction, Consolidation, and Maintenance in Subjects With High Risk Smoldering Multiple Myeloma (SMM)",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Smoldering Multiple Myeloma"
          ],
          "lead_sponsor": "International Myeloma Foundation",
          "collaborators": [
            "Amgen",
            "Janssen Scientific Affairs, LLC",
            "Celgene",
            "Trevie, Inc."
          ],
          "interventions": [
            "Carfilzomib",
            "Lenalidomide",
            "Daratumumab",
            "Dexamethasone"
          ],
          "last_update": "2023-12-12",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT03289299"
        },
        {
          "nct_id": "NCT04396496",
          "title": "A Phase II Trial for the Treatment of POEMS Syndrome With Daratumumab",
          "overall_status": "COMPLETED",
          "phase": "Phase 2",
          "conditions": [
            "POEMS Syndrome"
          ],
          "lead_sponsor": "University of Arkansas",
          "collaborators": [
            "Janssen Scientific Affairs, LLC"
          ],
          "interventions": [
            "Daratumumab Injection"
          ],
          "last_update": "2023-11-13",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04396496"
        },
        {
          "nct_id": "NCT03384654",
          "title": "An Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Subjects >=1 and <=30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma",
          "overall_status": "COMPLETED",
          "phase": "Phase 2",
          "conditions": [
            "Precursor Cell Lymphoblastic Leukemia-Lymphoma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Daratumumab",
            "Vincristine",
            "Prednisone",
            "Doxorubicin",
            "Peg-asparaginase",
            "Cyclophosphamide",
            "Cytarabine",
            "6-mercaptopurine",
            "Methotrexate"
          ],
          "last_update": "2025-05-25",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT03384654"
        },
        {
          "nct_id": "NCT07075510",
          "title": "A Phase I/II Study of Subcutaneous Daratumumab Administration in the Anterior Upper Thigh Vs Abdomen in Patients With Plasma Cell Disorders",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Plasma Cell Disorder"
          ],
          "lead_sponsor": "University of Maryland, Baltimore",
          "collaborators": [
            "Johnson & Johnson"
          ],
          "interventions": [
            "Daratumumab Injection"
          ],
          "last_update": "2025-10-29",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07075510"
        },
        {
          "nct_id": "NCT04140162",
          "title": "Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "University of Michigan Rogel Cancer Center",
          "collaborators": [
            "Janssen Scientific Affairs, LLC"
          ],
          "interventions": [
            "Daratumumab",
            "Lenalidomide",
            "Bortezomib",
            "Dexamethasone"
          ],
          "last_update": "2024-10-09",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04140162"
        },
        {
          "nct_id": "NCT05849610",
          "title": "An Open Label, Multicenter, Phase 2, Pilot Study, Evaluating Early Treatment With Bispecific T-cell Redirectors (Teclistamab and Talquetamab) in the Frontline Therapy of Newly Diagnosed High-risk Multiple Myeloma",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "High-Risk de Novo Multiple Myeloma"
          ],
          "lead_sponsor": "PETHEMA Foundation",
          "collaborators": [
            "Janssen Pharmaceutica N.V., Belgium"
          ],
          "interventions": [
            "Daratumumab",
            "Bortezomib",
            "Lenalidomide",
            "Teclistamab",
            "Talquetamab"
          ],
          "last_update": "2025-03-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05849610"
        },
        {
          "nct_id": "NCT03187262",
          "title": "A Phase 2 Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia",
          "overall_status": "COMPLETED",
          "phase": "Phase 2",
          "conditions": [
            "Waldenström Macroglobulinemia"
          ],
          "lead_sponsor": "Dana-Farber Cancer Institute",
          "collaborators": [
            "Janssen, LP"
          ],
          "interventions": [
            "Daratumumab"
          ],
          "last_update": "2022-11-23",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT03187262"
        },
        {
          "nct_id": "NCT03447808",
          "title": "Daratumumab and Ibrutinib for Symptomatic, Treatment-Naive CLL: A Phase 1b Proof-of-Concept Study",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Chronic Lymphocytic Leukemia"
          ],
          "lead_sponsor": "Jennifer Woyach",
          "collaborators": [],
          "interventions": [
            "Daratumumab",
            "Ibrutinib",
            "Laboratory Biomarker Analysis",
            "Pharmacological Study"
          ],
          "last_update": "2026-01-07",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT03447808"
        },
        {
          "nct_id": "NCT04910568",
          "title": "An Open-Label, Multicenter, Phase Ib Trial Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab as Monotherapy and Cevostamab Plus Pomalidomide and Dexamethasone or Cevostamab Plus Daratumumab and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Genentech, Inc.",
          "collaborators": [
            "Hoffmann-La Roche"
          ],
          "interventions": [
            "Cevostamab",
            "Tocilizumab",
            "Pomalidomide",
            "Daratumumab",
            "Dexamethasone"
          ],
          "last_update": "2025-12-24",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04910568"
        }
      ],
      "_ctgov_best_phase": "Phase 2",
      "_ctgov_phase_flag": "ok",
      "_ctgov_query_terms": [
        "DARZALEX (daratumumab)",
        "daratumumab",
        "DARZALEX"
      ]
    },
    {
      "asset": "DARZALEX (daratumumab)",
      "indication": "Frontline multiple myeloma transplant ineligible",
      "phase": null,
      "trial_or_program": "CEPHEUS",
      "partner": "Genmab A/S",
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT03500445",
          "title": "Open-label, Single-arm, Phase 2 Study of Initial Treatment With Daratumumab (Darzalex), Carfilzomib (Kyprolis), Lenalidomide (Revlimid) and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma Requiring Systemic Chemotherapy",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Myeloma",
            "Multiple Myeloma"
          ],
          "lead_sponsor": "University of Chicago",
          "collaborators": [
            "Janssen Scientific Affairs, LLC",
            "Amgen"
          ],
          "interventions": [
            "Daratumumab",
            "Carfilzomib",
            "Lenalidomide",
            "Dexamethasone"
          ],
          "last_update": "2025-10-03",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT03500445"
        },
        {
          "nct_id": "NCT03289299",
          "title": "Aggressive Smoldering Curative Approach Evaluating Novel Therapies (ASCENT): A Phase 2 Trial of Induction, Consolidation, and Maintenance in Subjects With High Risk Smoldering Multiple Myeloma (SMM)",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Smoldering Multiple Myeloma"
          ],
          "lead_sponsor": "International Myeloma Foundation",
          "collaborators": [
            "Amgen",
            "Janssen Scientific Affairs, LLC",
            "Celgene",
            "Trevie, Inc."
          ],
          "interventions": [
            "Carfilzomib",
            "Lenalidomide",
            "Daratumumab",
            "Dexamethasone"
          ],
          "last_update": "2023-12-12",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT03289299"
        },
        {
          "nct_id": "NCT04396496",
          "title": "A Phase II Trial for the Treatment of POEMS Syndrome With Daratumumab",
          "overall_status": "COMPLETED",
          "phase": "Phase 2",
          "conditions": [
            "POEMS Syndrome"
          ],
          "lead_sponsor": "University of Arkansas",
          "collaborators": [
            "Janssen Scientific Affairs, LLC"
          ],
          "interventions": [
            "Daratumumab Injection"
          ],
          "last_update": "2023-11-13",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04396496"
        },
        {
          "nct_id": "NCT03384654",
          "title": "An Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Subjects >=1 and <=30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma",
          "overall_status": "COMPLETED",
          "phase": "Phase 2",
          "conditions": [
            "Precursor Cell Lymphoblastic Leukemia-Lymphoma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Daratumumab",
            "Vincristine",
            "Prednisone",
            "Doxorubicin",
            "Peg-asparaginase",
            "Cyclophosphamide",
            "Cytarabine",
            "6-mercaptopurine",
            "Methotrexate"
          ],
          "last_update": "2025-05-25",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT03384654"
        },
        {
          "nct_id": "NCT07075510",
          "title": "A Phase I/II Study of Subcutaneous Daratumumab Administration in the Anterior Upper Thigh Vs Abdomen in Patients With Plasma Cell Disorders",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Plasma Cell Disorder"
          ],
          "lead_sponsor": "University of Maryland, Baltimore",
          "collaborators": [
            "Johnson & Johnson"
          ],
          "interventions": [
            "Daratumumab Injection"
          ],
          "last_update": "2025-10-29",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07075510"
        },
        {
          "nct_id": "NCT04140162",
          "title": "Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "University of Michigan Rogel Cancer Center",
          "collaborators": [
            "Janssen Scientific Affairs, LLC"
          ],
          "interventions": [
            "Daratumumab",
            "Lenalidomide",
            "Bortezomib",
            "Dexamethasone"
          ],
          "last_update": "2024-10-09",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04140162"
        },
        {
          "nct_id": "NCT05849610",
          "title": "An Open Label, Multicenter, Phase 2, Pilot Study, Evaluating Early Treatment With Bispecific T-cell Redirectors (Teclistamab and Talquetamab) in the Frontline Therapy of Newly Diagnosed High-risk Multiple Myeloma",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "High-Risk de Novo Multiple Myeloma"
          ],
          "lead_sponsor": "PETHEMA Foundation",
          "collaborators": [
            "Janssen Pharmaceutica N.V., Belgium"
          ],
          "interventions": [
            "Daratumumab",
            "Bortezomib",
            "Lenalidomide",
            "Teclistamab",
            "Talquetamab"
          ],
          "last_update": "2025-03-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05849610"
        },
        {
          "nct_id": "NCT03187262",
          "title": "A Phase 2 Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia",
          "overall_status": "COMPLETED",
          "phase": "Phase 2",
          "conditions": [
            "Waldenström Macroglobulinemia"
          ],
          "lead_sponsor": "Dana-Farber Cancer Institute",
          "collaborators": [
            "Janssen, LP"
          ],
          "interventions": [
            "Daratumumab"
          ],
          "last_update": "2022-11-23",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT03187262"
        },
        {
          "nct_id": "NCT03447808",
          "title": "Daratumumab and Ibrutinib for Symptomatic, Treatment-Naive CLL: A Phase 1b Proof-of-Concept Study",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Chronic Lymphocytic Leukemia"
          ],
          "lead_sponsor": "Jennifer Woyach",
          "collaborators": [],
          "interventions": [
            "Daratumumab",
            "Ibrutinib",
            "Laboratory Biomarker Analysis",
            "Pharmacological Study"
          ],
          "last_update": "2026-01-07",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT03447808"
        },
        {
          "nct_id": "NCT04910568",
          "title": "An Open-Label, Multicenter, Phase Ib Trial Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab as Monotherapy and Cevostamab Plus Pomalidomide and Dexamethasone or Cevostamab Plus Daratumumab and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Genentech, Inc.",
          "collaborators": [
            "Hoffmann-La Roche"
          ],
          "interventions": [
            "Cevostamab",
            "Tocilizumab",
            "Pomalidomide",
            "Daratumumab",
            "Dexamethasone"
          ],
          "last_update": "2025-12-24",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04910568"
        }
      ],
      "_ctgov_best_phase": "Phase 2",
      "_ctgov_phase_flag": "ok",
      "_ctgov_query_terms": [
        "DARZALEX (daratumumab)",
        "daratumumab",
        "DARZALEX"
      ]
    },
    {
      "asset": "IMBRUVICA (ibrutinib)",
      "indication": "Frontline Chronic Lymphocytic Leukemia (I + V fixed duration)",
      "phase": null,
      "trial_or_program": "GLOW",
      "partner": "Pharmacyclics, LLC, an AbbVie company",
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT04010968",
          "title": "Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia: a Randomized Phase II Trial Comparing FCR and a Chemo-free Combination of Venetoclax and Ibrutinib. A FILO Study",
          "overall_status": "COMPLETED",
          "phase": "Phase 2",
          "conditions": [
            "Intermediate Risk Chronic Lymphocytic Leukemia",
            "Fit Patients",
            "Risk-Adapted and MRD-Driven Strategy"
          ],
          "lead_sponsor": "French Innovative Leukemia Organisation",
          "collaborators": [
            "AbbVie",
            "Janssen-Cilag Ltd."
          ],
          "interventions": [
            "venetoclax and ibrutinib (I+VEN)",
            "FCR"
          ],
          "last_update": "2025-11-26",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04010968"
        },
        {
          "nct_id": "NCT02315326",
          "title": "A Phase I/II Trial of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL)",
            "Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)"
          ],
          "lead_sponsor": "Memorial Sloan Kettering Cancer Center",
          "collaborators": [
            "Pharmacyclics LLC.",
            "Janssen Biotech, Inc."
          ],
          "interventions": [
            "Ibrutinib",
            "HD- Methotrexate (MTX)",
            "Rituximab + HD- Methotrexate (MTX)",
            "procarbazine"
          ],
          "last_update": "2025-07-01",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT02315326"
        },
        {
          "nct_id": "NCT02824159",
          "title": "Real Life Assessment of the Association and Its Determinants Between Side Effects and Plasmatic Concentrations of Two Protein Kinase Inhibitors: Ibrutinib (IMBRUVICA®) and Idelalisib (ZYDELIG®) in Hematological Malignancies Treatment.",
          "overall_status": "COMPLETED",
          "phase": null,
          "conditions": [
            "Hematological Malignancies"
          ],
          "lead_sponsor": "University Hospital, Toulouse",
          "collaborators": [],
          "interventions": [
            "Blood samples for pharmacokinetics exploration",
            "Imagery",
            "Quality of life scale",
            "Detection of adverse events",
            "Saliva samples",
            "Blood sample",
            "Biological statement",
            "Clinical examination"
          ],
          "last_update": "2020-12-28",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT02824159"
        },
        {
          "nct_id": "NCT03447808",
          "title": "Daratumumab and Ibrutinib for Symptomatic, Treatment-Naive CLL: A Phase 1b Proof-of-Concept Study",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Chronic Lymphocytic Leukemia"
          ],
          "lead_sponsor": "Jennifer Woyach",
          "collaborators": [],
          "interventions": [
            "Daratumumab",
            "Ibrutinib",
            "Laboratory Biomarker Analysis",
            "Pharmacological Study"
          ],
          "last_update": "2026-01-07",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT03447808"
        },
        {
          "nct_id": "NCT06649812",
          "title": "A Phase 2 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed or Refractory CD10-Negative Diffuse-Large B-Cell Lymphoma (DLBCL) and High-Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements (HGBCL-DH-BCL2)",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements",
            "Recurrent Diffuse Large B-Cell Lymphoma",
            "Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type",
            "Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified",
            "Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements",
            "Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements",
            "Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified",
            "Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma",
            "Refractory Diffuse Large B-Cell Lymphoma",
            "Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type"
          ],
          "lead_sponsor": "National Cancer Institute (NCI)",
          "collaborators": [],
          "interventions": [
            "Biopsy Procedure",
            "Biospecimen Collection",
            "Bone Marrow Aspiration",
            "Bone Marrow Biopsy",
            "Computed Tomography",
            "Ibrutinib",
            "Lenalidomide",
            "Magnetic Resonance Imaging",
            "Obinutuzumab",
            "Positron Emission Tomography"
          ],
          "last_update": "2025-12-30",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06649812"
        },
        {
          "nct_id": "NCT03478514",
          "title": "A Phase II Study of Palbociclib (PD-0332991) in Combination With Ibrutinib in Patients With Previously Treated Mantle Cell Lymphoma",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Mantle Cell Lymphoma",
            "B Cell Lymphoma"
          ],
          "lead_sponsor": "Alliance Foundation Trials, LLC.",
          "collaborators": [
            "Pfizer"
          ],
          "interventions": [
            "Palbociclib",
            "Ibrutinib"
          ],
          "last_update": "2025-12-18",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT03478514"
        },
        {
          "nct_id": "NCT02827617",
          "title": "Prospective, Observational, Multi-centred, Non-interventional Study on the Identification of Biomarkers That Are Predictive of Early Ibrutinib Treatment Failure in High Risk TP53 Mutated Chronic Lymphocytic Leukemia",
          "overall_status": "COMPLETED",
          "phase": null,
          "conditions": [
            "Chronic Lymphocytic Leukemia"
          ],
          "lead_sponsor": "Oncology Institute of Southern Switzerland",
          "collaborators": [],
          "interventions": [
            "Ibrutinib"
          ],
          "last_update": "2025-11-18",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT02827617"
        },
        {
          "nct_id": "NCT02420912",
          "title": "Nivolumab Combined With Ibrutinib for Relapsed, Refractory or High-Risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL)",
          "overall_status": "COMPLETED",
          "phase": "Phase 2",
          "conditions": [
            "Loss of Chromosome 17p",
            "Recurrent Chronic Lymphocytic Leukemia",
            "Recurrent Small Lymphocytic Lymphoma",
            "Refractory Chronic Lymphocytic Leukemia",
            "Refractory Small Lymphocytic Lymphoma",
            "Richter Syndrome"
          ],
          "lead_sponsor": "M.D. Anderson Cancer Center",
          "collaborators": [
            "National Cancer Institute (NCI)"
          ],
          "interventions": [
            "Ibrutinib",
            "Laboratory Biomarker Analysis",
            "Nivolumab"
          ],
          "last_update": "2024-03-20",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT02420912"
        },
        {
          "nct_id": "NCT02824029",
          "title": "A Phase II Multicenter Single Arm Study to Evaluate the Efficacy and Safety of Single Agent Bruton's Tyrosine Kinase Inhibitor, Ibrutinib, in Patients With Relapsed Refractory Classical Hodgkin's Lymphoma",
          "overall_status": "COMPLETED",
          "phase": "Phase 2",
          "conditions": [
            "Classical Hodgkin Lymphoma",
            "Recurrent Hodgkin Lymphoma",
            "Refractory Hodgkin Lymphoma"
          ],
          "lead_sponsor": "Barbara Ann Karmanos Cancer Institute",
          "collaborators": [
            "National Cancer Institute (NCI)"
          ],
          "interventions": [
            "Ibrutinib",
            "Laboratory Biomarker Analysis",
            "Pharmacological Study"
          ],
          "last_update": "2025-02-17",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT02824029"
        },
        {
          "nct_id": "NCT02514083",
          "title": "A Pilot Phase II Study Using Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Chronic Lymphocytic Leukemia",
            "Small Lymphocytic Lymphoma"
          ],
          "lead_sponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
          "collaborators": [],
          "interventions": [
            "Ibrutinib",
            "Fludarabine"
          ],
          "last_update": "2024-09-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT02514083"
        }
      ],
      "_ctgov_best_phase": "Phase 2",
      "_ctgov_phase_flag": "ok",
      "_ctgov_query_terms": [
        "IMBRUVICA (ibrutinib)",
        "ibrutinib",
        "IMBRUVICA"
      ]
    },
    {
      "asset": "IMBRUVICA (ibrutinib)",
      "indication": "Frontline Mantle Cell Lymphoma",
      "phase": null,
      "trial_or_program": "Triangle",
      "partner": "Pharmacyclics, LLC, an AbbVie company",
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT04010968",
          "title": "Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia: a Randomized Phase II Trial Comparing FCR and a Chemo-free Combination of Venetoclax and Ibrutinib. A FILO Study",
          "overall_status": "COMPLETED",
          "phase": "Phase 2",
          "conditions": [
            "Intermediate Risk Chronic Lymphocytic Leukemia",
            "Fit Patients",
            "Risk-Adapted and MRD-Driven Strategy"
          ],
          "lead_sponsor": "French Innovative Leukemia Organisation",
          "collaborators": [
            "AbbVie",
            "Janssen-Cilag Ltd."
          ],
          "interventions": [
            "venetoclax and ibrutinib (I+VEN)",
            "FCR"
          ],
          "last_update": "2025-11-26",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04010968"
        },
        {
          "nct_id": "NCT02315326",
          "title": "A Phase I/II Trial of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL)",
            "Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)"
          ],
          "lead_sponsor": "Memorial Sloan Kettering Cancer Center",
          "collaborators": [
            "Pharmacyclics LLC.",
            "Janssen Biotech, Inc."
          ],
          "interventions": [
            "Ibrutinib",
            "HD- Methotrexate (MTX)",
            "Rituximab + HD- Methotrexate (MTX)",
            "procarbazine"
          ],
          "last_update": "2025-07-01",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT02315326"
        },
        {
          "nct_id": "NCT02824159",
          "title": "Real Life Assessment of the Association and Its Determinants Between Side Effects and Plasmatic Concentrations of Two Protein Kinase Inhibitors: Ibrutinib (IMBRUVICA®) and Idelalisib (ZYDELIG®) in Hematological Malignancies Treatment.",
          "overall_status": "COMPLETED",
          "phase": null,
          "conditions": [
            "Hematological Malignancies"
          ],
          "lead_sponsor": "University Hospital, Toulouse",
          "collaborators": [],
          "interventions": [
            "Blood samples for pharmacokinetics exploration",
            "Imagery",
            "Quality of life scale",
            "Detection of adverse events",
            "Saliva samples",
            "Blood sample",
            "Biological statement",
            "Clinical examination"
          ],
          "last_update": "2020-12-28",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT02824159"
        },
        {
          "nct_id": "NCT03447808",
          "title": "Daratumumab and Ibrutinib for Symptomatic, Treatment-Naive CLL: A Phase 1b Proof-of-Concept Study",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Chronic Lymphocytic Leukemia"
          ],
          "lead_sponsor": "Jennifer Woyach",
          "collaborators": [],
          "interventions": [
            "Daratumumab",
            "Ibrutinib",
            "Laboratory Biomarker Analysis",
            "Pharmacological Study"
          ],
          "last_update": "2026-01-07",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT03447808"
        },
        {
          "nct_id": "NCT06649812",
          "title": "A Phase 2 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed or Refractory CD10-Negative Diffuse-Large B-Cell Lymphoma (DLBCL) and High-Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements (HGBCL-DH-BCL2)",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements",
            "Recurrent Diffuse Large B-Cell Lymphoma",
            "Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type",
            "Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified",
            "Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements",
            "Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements",
            "Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified",
            "Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma",
            "Refractory Diffuse Large B-Cell Lymphoma",
            "Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type"
          ],
          "lead_sponsor": "National Cancer Institute (NCI)",
          "collaborators": [],
          "interventions": [
            "Biopsy Procedure",
            "Biospecimen Collection",
            "Bone Marrow Aspiration",
            "Bone Marrow Biopsy",
            "Computed Tomography",
            "Ibrutinib",
            "Lenalidomide",
            "Magnetic Resonance Imaging",
            "Obinutuzumab",
            "Positron Emission Tomography"
          ],
          "last_update": "2025-12-30",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06649812"
        },
        {
          "nct_id": "NCT03478514",
          "title": "A Phase II Study of Palbociclib (PD-0332991) in Combination With Ibrutinib in Patients With Previously Treated Mantle Cell Lymphoma",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Mantle Cell Lymphoma",
            "B Cell Lymphoma"
          ],
          "lead_sponsor": "Alliance Foundation Trials, LLC.",
          "collaborators": [
            "Pfizer"
          ],
          "interventions": [
            "Palbociclib",
            "Ibrutinib"
          ],
          "last_update": "2025-12-18",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT03478514"
        },
        {
          "nct_id": "NCT02827617",
          "title": "Prospective, Observational, Multi-centred, Non-interventional Study on the Identification of Biomarkers That Are Predictive of Early Ibrutinib Treatment Failure in High Risk TP53 Mutated Chronic Lymphocytic Leukemia",
          "overall_status": "COMPLETED",
          "phase": null,
          "conditions": [
            "Chronic Lymphocytic Leukemia"
          ],
          "lead_sponsor": "Oncology Institute of Southern Switzerland",
          "collaborators": [],
          "interventions": [
            "Ibrutinib"
          ],
          "last_update": "2025-11-18",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT02827617"
        },
        {
          "nct_id": "NCT02420912",
          "title": "Nivolumab Combined With Ibrutinib for Relapsed, Refractory or High-Risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL)",
          "overall_status": "COMPLETED",
          "phase": "Phase 2",
          "conditions": [
            "Loss of Chromosome 17p",
            "Recurrent Chronic Lymphocytic Leukemia",
            "Recurrent Small Lymphocytic Lymphoma",
            "Refractory Chronic Lymphocytic Leukemia",
            "Refractory Small Lymphocytic Lymphoma",
            "Richter Syndrome"
          ],
          "lead_sponsor": "M.D. Anderson Cancer Center",
          "collaborators": [
            "National Cancer Institute (NCI)"
          ],
          "interventions": [
            "Ibrutinib",
            "Laboratory Biomarker Analysis",
            "Nivolumab"
          ],
          "last_update": "2024-03-20",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT02420912"
        },
        {
          "nct_id": "NCT02824029",
          "title": "A Phase II Multicenter Single Arm Study to Evaluate the Efficacy and Safety of Single Agent Bruton's Tyrosine Kinase Inhibitor, Ibrutinib, in Patients With Relapsed Refractory Classical Hodgkin's Lymphoma",
          "overall_status": "COMPLETED",
          "phase": "Phase 2",
          "conditions": [
            "Classical Hodgkin Lymphoma",
            "Recurrent Hodgkin Lymphoma",
            "Refractory Hodgkin Lymphoma"
          ],
          "lead_sponsor": "Barbara Ann Karmanos Cancer Institute",
          "collaborators": [
            "National Cancer Institute (NCI)"
          ],
          "interventions": [
            "Ibrutinib",
            "Laboratory Biomarker Analysis",
            "Pharmacological Study"
          ],
          "last_update": "2025-02-17",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT02824029"
        },
        {
          "nct_id": "NCT02514083",
          "title": "A Pilot Phase II Study Using Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Chronic Lymphocytic Leukemia",
            "Small Lymphocytic Lymphoma"
          ],
          "lead_sponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
          "collaborators": [],
          "interventions": [
            "Ibrutinib",
            "Fludarabine"
          ],
          "last_update": "2024-09-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT02514083"
        }
      ],
      "_ctgov_best_phase": "Phase 2",
      "_ctgov_phase_flag": "ok",
      "_ctgov_query_terms": [
        "IMBRUVICA (ibrutinib)",
        "ibrutinib",
        "IMBRUVICA"
      ]
    },
    {
      "asset": "INLEXZO (gemcitabine intravesical system)",
      "indication": "Non Muscle Invasive Bladder Cancer",
      "phase": null,
      "trial_or_program": "SunRISe-1",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT04658862",
          "title": "A Phase 3, Multi-center, Randomized Study Evaluating Efficacy of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder Who Are Not Receiving Radical Cystectomy",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Urinary Bladder Neoplasms"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Cetrelimab",
            "TAR-200",
            "Cisplatin",
            "Gemcitabine",
            "Conventional radiation therapy",
            "Hypo-fractioned radiation therapy"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04658862"
        },
        {
          "nct_id": "NCT06319820",
          "title": "A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Non-Muscle Invasive Bladder Cancer"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "TAR-210",
            "Gemcitabine",
            "MMC"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06319820"
        },
        {
          "nct_id": "NCT04640623",
          "title": "Phase 2b Clinical Study Evaluating Efficacy and Safety of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin (BCG) Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Urinary Bladder Neoplasms"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "TAR-200",
            "Cetrelimab"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04640623"
        },
        {
          "nct_id": "NCT06919965",
          "title": "A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Investigator's Choice of Intravesical Chemotherapy in Participants With High-risk Non-muscle-invasive Bladder Cancer With Susceptible FGFR Alterations Who Had Received Intravesical Bacillus Calmette-Guérin (BCG)",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Non-Muscle Invasive Bladder Neoplasms"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "TAR-210",
            "Mitomycin C",
            "Gemcitabine"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06919965"
        },
        {
          "nct_id": "NCT03404791",
          "title": "A Multicenter Study Evaluating Safety and Efficacy of TAR-200 in Subjects With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical Cystectomy",
          "overall_status": "COMPLETED",
          "phase": "Phase 1",
          "conditions": [
            "Urinary Bladder Neoplasms"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "TAR-200"
          ],
          "last_update": "2025-02-04",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT03404791"
        },
        {
          "nct_id": "NCT04172675",
          "title": "A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) and FGFR Mutations or Fusions",
          "overall_status": "COMPLETED",
          "phase": "Phase 2",
          "conditions": [
            "Urinary Bladder Neoplasms"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Erdafitinib",
            "Investigator Choice (Gemcitabine)",
            "Investigator Choice (Mitomycin C)"
          ],
          "last_update": "2025-08-01",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04172675"
        },
        {
          "nct_id": "NCT07000084",
          "title": "GAIN-BCG: Gemcitabine Alternating With INtravesical BCG Randomized Against BCG Alone for Patients With Recurrent High Grade Non-Muscle Invasive Bladder Cancer",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Recurrent Non-Muscle Invasive Bladder Carcinoma",
            "Stage 0a Bladder Cancer AJCC v8",
            "Stage I Bladder Cancer AJCC v8"
          ],
          "lead_sponsor": "Alliance for Clinical Trials in Oncology",
          "collaborators": [
            "National Cancer Institute (NCI)"
          ],
          "interventions": [
            "BCG Solution",
            "Biopsy of Bladder",
            "Cystoscopy",
            "Computed Tomography",
            "Magnetic Resonance Imaging",
            "Biospecimen Collection",
            "Transurethral Resection of Bladder Tumor",
            "Gemcitabine"
          ],
          "last_update": "2026-01-07",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07000084"
        },
        {
          "nct_id": "NCT07307456",
          "title": "A Prospective, Open-label, Single-center Clinical Study Evaluating the Efficacy and Safety of Trastuzumab Combined With BCG Perfusion as an Adjuvant Treatment After TURBT in High-risk/Very High-risk Non-muscle-invasive Bladder Cancer",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Bladder Cancer"
          ],
          "lead_sponsor": "Changhai Hospital",
          "collaborators": [],
          "interventions": [
            "Treatment with toripalimab combined with BCG perfusion following transurethral resection of bladder tumor (TURBT)"
          ],
          "last_update": "2025-12-29",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07307456"
        },
        {
          "nct_id": "NCT05538663",
          "title": "A Randomized Phase III Trial of Intravesical BCG veRsus Intravesical Docetaxel and GEmcitabine Treatment in BCG Naïve High Grade Non-Muscle Invasive Bladder Cancer (BRIDGE)",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Non-muscle-invasive Bladder Cancer"
          ],
          "lead_sponsor": "ECOG-ACRIN Cancer Research Group",
          "collaborators": [
            "National Cancer Institute (NCI)"
          ],
          "interventions": [
            "Gemcitabine",
            "Docetaxel",
            "Bacillus Calmette Guerin"
          ],
          "last_update": "2025-12-30",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05538663"
        },
        {
          "nct_id": "NCT06545955",
          "title": "A Phase 3, Randomised, Multi-center, Open Label Trial to Evaluate the Safety and Efficacy of Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade Bacillus Calmette-Guerin Therapy (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC)",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Non-muscle Invasive Bladder Cancer With Carcinoma in Situ"
          ],
          "lead_sponsor": "Ferring Pharmaceuticals",
          "collaborators": [],
          "interventions": [
            "Nadofaragene Firadenovec",
            "Gemcitabine",
            "Docetaxel",
            "Pembrolizumab"
          ],
          "last_update": "2026-01-06",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06545955"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok",
      "_ctgov_query_terms": [
        "INLEXZO (gemcitabine intravesical system)",
        "gemcitabine intravesical system",
        "INLEXZO"
      ]
    },
    {
      "asset": "RYBREVANT (amivantamab)",
      "indication": "Frontline Non Small Cell Lung Cancer in combination with chemotherapy",
      "phase": null,
      "trial_or_program": "PAPILLON",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT05379595",
          "title": "A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Advanced or Metastatic Colorectal Cancer"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Amivantamab IV",
            "Fluorouracil",
            "Leucovorin",
            "Oxaliplatin",
            "Irinotecan",
            "Amivantamab"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05379595"
        },
        {
          "nct_id": "NCT07276399",
          "title": "A Phase 3, Randomized, Open-Label, Multicenter Study of Amivantamab in Addition to Carboplatin and Pembrolizumab, Compared to Standard of Care Platinum and Pembrolizumab and 5-FU, in Participants With Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Squamous Cell Carcinoma of Head and Neck"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Amivantamab",
            "Pembrolizumab",
            "Carboplatin",
            "5-Flurouracil",
            "Cisplatin"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07276399"
        },
        {
          "nct_id": "NCT07227025",
          "title": "A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Olomorasib Combination Therapy in Metastatic Non-small Cell Lung Cancer",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Carcinoma, Non-Small-Cell Lung"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Amivantamab",
            "Olomorasib"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07227025"
        },
        {
          "nct_id": "NCT04988295",
          "title": "A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Carcinoma, Non-Small-Cell Lung"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Lazertinib",
            "Amivantamab",
            "Pemetrexed",
            "Carboplatin"
          ],
          "last_update": "2025-12-23",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04988295"
        },
        {
          "nct_id": "NCT04606381",
          "title": "An Open-label, Multicenter, Dose Escalation Phase 1b Study to Assess the Safety and Pharmacokinetics of Subcutaneous Delivery of Amivantamab, a Human Bispecific EGFR and cMet Antibody for the Treatment of Advanced Solid Malignancies",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Advanced Solid Malignancies"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Ami-LC-MD",
            "Ami-LC",
            "Ami-HC",
            "Ami-HC-CF",
            "Lazertinib"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04606381"
        },
        {
          "nct_id": "NCT04538664",
          "title": "A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Patients With EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Carcinoma, Non-Small-Cell Lung"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Amivantamab",
            "Pemetrexed",
            "Carboplatin",
            "Pemetrexed"
          ],
          "last_update": "2025-12-23",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04538664"
        },
        {
          "nct_id": "NCT04077463",
          "title": "An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ-73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non-Small Cell Lung Cancer",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Carcinoma, Non-Small-Cell Lung"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Lazertinib",
            "Amivantamab",
            "Carboplatin",
            "Pemetrexed"
          ],
          "last_update": "2025-12-24",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04077463"
        },
        {
          "nct_id": "NCT06532032",
          "title": "A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Docetaxel Combination Therapy in Metastatic Non-small Cell Lung Cancer",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Carcinoma, Non-Small-Cell Lung"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Amivantamab",
            "Docetaxel"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06532032"
        },
        {
          "nct_id": "NCT02609776",
          "title": "A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects With Advanced Non-Small Cell Lung Cancer",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Non-Small-Cell Lung Cancer"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Amivantamab",
            "Amivantamab",
            "Lazertinib",
            "Carboplatin",
            "Pemetrexed"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT02609776"
        },
        {
          "nct_id": "NCT04487080",
          "title": "A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer.",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Carcinoma, Non-Small-Cell Lung"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Amivantamab",
            "Osimertinib",
            "Lazertinib",
            "Placebo"
          ],
          "last_update": "2025-12-23",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04487080"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok",
      "_ctgov_query_terms": [
        "RYBREVANT (amivantamab)",
        "amivantamab",
        "RYBREVANT"
      ]
    },
    {
      "asset": "RYBREVANT (amivantamab)",
      "indication": null,
      "phase": null,
      "trial_or_program": "PALOMA-3",
      "partner": null,
      "notes": "Subcutaneous",
      "_ctgov_matches": [
        {
          "nct_id": "NCT05379595",
          "title": "A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Advanced or Metastatic Colorectal Cancer"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Amivantamab IV",
            "Fluorouracil",
            "Leucovorin",
            "Oxaliplatin",
            "Irinotecan",
            "Amivantamab"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05379595"
        },
        {
          "nct_id": "NCT07276399",
          "title": "A Phase 3, Randomized, Open-Label, Multicenter Study of Amivantamab in Addition to Carboplatin and Pembrolizumab, Compared to Standard of Care Platinum and Pembrolizumab and 5-FU, in Participants With Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Squamous Cell Carcinoma of Head and Neck"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Amivantamab",
            "Pembrolizumab",
            "Carboplatin",
            "5-Flurouracil",
            "Cisplatin"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07276399"
        },
        {
          "nct_id": "NCT07227025",
          "title": "A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Olomorasib Combination Therapy in Metastatic Non-small Cell Lung Cancer",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Carcinoma, Non-Small-Cell Lung"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Amivantamab",
            "Olomorasib"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07227025"
        },
        {
          "nct_id": "NCT04988295",
          "title": "A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Carcinoma, Non-Small-Cell Lung"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Lazertinib",
            "Amivantamab",
            "Pemetrexed",
            "Carboplatin"
          ],
          "last_update": "2025-12-23",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04988295"
        },
        {
          "nct_id": "NCT04606381",
          "title": "An Open-label, Multicenter, Dose Escalation Phase 1b Study to Assess the Safety and Pharmacokinetics of Subcutaneous Delivery of Amivantamab, a Human Bispecific EGFR and cMet Antibody for the Treatment of Advanced Solid Malignancies",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Advanced Solid Malignancies"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Ami-LC-MD",
            "Ami-LC",
            "Ami-HC",
            "Ami-HC-CF",
            "Lazertinib"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04606381"
        },
        {
          "nct_id": "NCT04538664",
          "title": "A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Patients With EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Carcinoma, Non-Small-Cell Lung"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Amivantamab",
            "Pemetrexed",
            "Carboplatin",
            "Pemetrexed"
          ],
          "last_update": "2025-12-23",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04538664"
        },
        {
          "nct_id": "NCT04077463",
          "title": "An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ-73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non-Small Cell Lung Cancer",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Carcinoma, Non-Small-Cell Lung"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Lazertinib",
            "Amivantamab",
            "Carboplatin",
            "Pemetrexed"
          ],
          "last_update": "2025-12-24",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04077463"
        },
        {
          "nct_id": "NCT06532032",
          "title": "A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Docetaxel Combination Therapy in Metastatic Non-small Cell Lung Cancer",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Carcinoma, Non-Small-Cell Lung"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Amivantamab",
            "Docetaxel"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06532032"
        },
        {
          "nct_id": "NCT02609776",
          "title": "A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects With Advanced Non-Small Cell Lung Cancer",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Non-Small-Cell Lung Cancer"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Amivantamab",
            "Amivantamab",
            "Lazertinib",
            "Carboplatin",
            "Pemetrexed"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT02609776"
        },
        {
          "nct_id": "NCT04487080",
          "title": "A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer.",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Carcinoma, Non-Small-Cell Lung"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Amivantamab",
            "Osimertinib",
            "Lazertinib",
            "Placebo"
          ],
          "last_update": "2025-12-23",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04487080"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok",
      "_ctgov_query_terms": [
        "RYBREVANT (amivantamab)",
        "amivantamab",
        "RYBREVANT"
      ]
    },
    {
      "asset": "Bleximenib",
      "indication": "Newly Diagnosed AML, chemo ineligible in combination with Venetoclax and Azacitidine",
      "phase": null,
      "trial_or_program": "cAMeLot-2",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT06852222",
          "title": "A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2A Rearrangements or NPM1 Mutations Who Are Ineligible for Intensive Chemotherapy",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Leukemia, Myeloid, Acute"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Bleximenib",
            "Venetoclax (VEN)",
            "Azacitidine (AZA)",
            "Placebo"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06852222"
        },
        {
          "nct_id": "NCT07295951",
          "title": "An Open-Label Study to Investigate the Absorption, Metabolism, And Excretion (AME) Of 14C-Bleximenib (JNJ-75276617) in Participants With Acute Leukemia",
          "overall_status": "RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Acute Lymphoblastic Leukemia",
            "Acute Leukemias",
            "Acute Myeloid Leukemia"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "14C-bleximenib",
            "bleximenib"
          ],
          "last_update": "2025-12-22",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07295951"
        },
        {
          "nct_id": "NCT05453903",
          "title": "A Phase 1b Study of Bleximenib in Combination With AML-Directed Therapies for Participants With Acute Myeloid Leukemia Harboring KMT2A or NPM1 Alterations",
          "overall_status": "RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Leukemia, Myeloid, Acute"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Bleximenib",
            "Venetoclax (VEN)",
            "Azacitidine (AZA)",
            "Cytarabine",
            "Daunorubicin or Idarubicin"
          ],
          "last_update": "2025-12-24",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05453903"
        },
        {
          "nct_id": "NCT04811560",
          "title": "A Phase 1/2, First-in-Human Study of the Menin-KMT2A (MLL1) Inhibitor Bleximenib in Participants With Acute Leukemia (cAMeLot-1)",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Acute Leukemias",
            "Acute Myeloid Leukemia",
            "Acute Lymphoblastic Leukemia"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Bleximenib"
          ],
          "last_update": "2025-12-10",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04811560"
        },
        {
          "nct_id": "NCT07223814",
          "title": "Bleximenib or Placebo in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for the Treatment of Patients With Newly Diagnosed KMT2A-rearranged or NPM1-mutant Acute Myeloid Leukemia Eligible for Intensive Chemotherapy: a Double-blind Phase 3 Study",
          "overall_status": "NOT_YET_RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Acute Myeloid Leukemia"
          ],
          "lead_sponsor": "Stichting Hemato-Oncologie voor Volwassenen Nederland",
          "collaborators": [
            "German-Austrian Acute Myeloid Leukemia Study Group"
          ],
          "interventions": [
            "Bleximenib",
            "Cytarabine",
            "Daunorubicin or Idarubicin",
            "Placebo"
          ],
          "last_update": "2025-11-03",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07223814"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok",
      "_ctgov_query_terms": [
        "Bleximenib"
      ]
    },
    {
      "asset": "CARVYKTI (Ciltacabtagene autoleucel)",
      "indication": "Frontline Multiple Myeloma TNI",
      "phase": null,
      "trial_or_program": "CARTITUDE-5",
      "partner": "Legend Biotech",
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT06623630",
          "title": "A Pilot Safety and Feasibility Study of Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function",
          "overall_status": "RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Washington University School of Medicine",
          "collaborators": [
            "American Cancer Society, Inc.",
            "Cures Within Reach"
          ],
          "interventions": [
            "Cyclophosphamide",
            "Ciltacabtagene Autoleucel",
            "Total body irradiation"
          ],
          "last_update": "2025-12-29",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06623630"
        },
        {
          "nct_id": "NCT07149857",
          "title": "A Phase 2 Multicohort Trial to Further Characterize the Efficacy and Safety of Ciltacabtagene Autoleucel",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Cilta-cel",
            "Cyclophosphamide",
            "Induction therapy",
            "Fludarabine"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07149857"
        },
        {
          "nct_id": "NCT05257083",
          "title": "A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Stichting European Myeloma Network",
          "collaborators": [
            "Janssen Research & Development, LLC"
          ],
          "interventions": [
            "Daratumumab",
            "Bortezomib",
            "Lenalidomide",
            "Dexamethasone",
            "Cilta-cel",
            "Cyclophosphamide",
            "Fludarabine"
          ],
          "last_update": "2025-12-18",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05257083"
        },
        {
          "nct_id": "NCT04923893",
          "title": "A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA Versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Bortezomib",
            "Dexamethasone",
            "Lenalidomide",
            "Cilta-cel",
            "Cyclophosphamide",
            "Fludarabine"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04923893"
        },
        {
          "nct_id": "NCT06577025",
          "title": "A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Different Sequences of Ciltacabtagene Autoleucel (Cilta-cel), Talquetamab SC in Combination With Daratumumab SC (Tal-D) and Teclistamab SC in Combination With Daratumumab SC (Tec-D) Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) in Participants With Standard-risk Newly Diagnosed Multiple Myeloma",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Cilta-cel",
            "Talquetamab",
            "Daratumumab",
            "Teclistamab",
            "Bortezomib",
            "Lenalidomide",
            "Dexamethasone",
            "Cyclophosphamide",
            "Fludarabine"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06577025"
        },
        {
          "nct_id": "NCT05201781",
          "title": "Long-term Follow-up Study for Participants Previously Treated With Ciltacabtagene Autoleucel",
          "overall_status": "RECRUITING",
          "phase": null,
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Cilta-cel"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05201781"
        },
        {
          "nct_id": "NCT05346835",
          "title": "Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-cel) Out-of-Specification (OOS) in Patients With Multiple Myeloma",
          "overall_status": "AVAILABLE",
          "phase": null,
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Scientific Affairs, LLC",
          "collaborators": [],
          "interventions": [
            "Cilta-cel OOS Therapy"
          ],
          "last_update": "2025-08-27",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05346835"
        },
        {
          "nct_id": "NCT05767359",
          "title": "CAR- PRISM (PRecision Intervention Smoldering Myeloma): A Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in High-Risk Smoldering Myeloma",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma",
            "Smoldering Multiple Myeloma"
          ],
          "lead_sponsor": "Dana-Farber Cancer Institute",
          "collaborators": [
            "Janssen Research & Development, LLC"
          ],
          "interventions": [
            "Ciltacabtagene Autoleucel",
            "Cyclophosphamide",
            "Fludarabine Phosphate"
          ],
          "last_update": "2025-09-11",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05767359"
        },
        {
          "nct_id": "NCT05347485",
          "title": "A Safety and Efficacy Study of JNJ-68284528 (Ciltacabtagene Autoleucel) Out-of-Specification (OOS) for Commercial Release in Patients With Multiple Myeloma",
          "overall_status": "COMPLETED",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Scientific Affairs, LLC",
          "collaborators": [],
          "interventions": [
            "Cilta-cel",
            "Lymphodepleting Therapy (Cyclophosphamide and Fludarabine)"
          ],
          "last_update": "2025-04-25",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05347485"
        },
        {
          "nct_id": "NCT07093554",
          "title": "Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma",
          "overall_status": "RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Relapse Multiple Myeloma",
            "Refractory Multiple Myeloma"
          ],
          "lead_sponsor": "Medical College of Wisconsin",
          "collaborators": [],
          "interventions": [
            "Talquetamab",
            "Ciltacabtagene Autoleucel"
          ],
          "last_update": "2026-01-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07093554"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok",
      "_ctgov_query_terms": [
        "CARVYKTI (Ciltacabtagene autoleucel)",
        "Ciltacabtagene autoleucel",
        "CARVYKTI"
      ]
    },
    {
      "asset": "CARVYKTI (Ciltacabtagene autoleucel)",
      "indication": "Frontline Multiple Myeloma Transplant Eligible vs ASCT",
      "phase": null,
      "trial_or_program": "CARTITUDE-6",
      "partner": "Legend Biotech",
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT06623630",
          "title": "A Pilot Safety and Feasibility Study of Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function",
          "overall_status": "RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Washington University School of Medicine",
          "collaborators": [
            "American Cancer Society, Inc.",
            "Cures Within Reach"
          ],
          "interventions": [
            "Cyclophosphamide",
            "Ciltacabtagene Autoleucel",
            "Total body irradiation"
          ],
          "last_update": "2025-12-29",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06623630"
        },
        {
          "nct_id": "NCT07149857",
          "title": "A Phase 2 Multicohort Trial to Further Characterize the Efficacy and Safety of Ciltacabtagene Autoleucel",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Cilta-cel",
            "Cyclophosphamide",
            "Induction therapy",
            "Fludarabine"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07149857"
        },
        {
          "nct_id": "NCT05257083",
          "title": "A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Stichting European Myeloma Network",
          "collaborators": [
            "Janssen Research & Development, LLC"
          ],
          "interventions": [
            "Daratumumab",
            "Bortezomib",
            "Lenalidomide",
            "Dexamethasone",
            "Cilta-cel",
            "Cyclophosphamide",
            "Fludarabine"
          ],
          "last_update": "2025-12-18",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05257083"
        },
        {
          "nct_id": "NCT04923893",
          "title": "A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA Versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Bortezomib",
            "Dexamethasone",
            "Lenalidomide",
            "Cilta-cel",
            "Cyclophosphamide",
            "Fludarabine"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04923893"
        },
        {
          "nct_id": "NCT06577025",
          "title": "A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Different Sequences of Ciltacabtagene Autoleucel (Cilta-cel), Talquetamab SC in Combination With Daratumumab SC (Tal-D) and Teclistamab SC in Combination With Daratumumab SC (Tec-D) Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) in Participants With Standard-risk Newly Diagnosed Multiple Myeloma",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Cilta-cel",
            "Talquetamab",
            "Daratumumab",
            "Teclistamab",
            "Bortezomib",
            "Lenalidomide",
            "Dexamethasone",
            "Cyclophosphamide",
            "Fludarabine"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06577025"
        },
        {
          "nct_id": "NCT05201781",
          "title": "Long-term Follow-up Study for Participants Previously Treated With Ciltacabtagene Autoleucel",
          "overall_status": "RECRUITING",
          "phase": null,
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Cilta-cel"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05201781"
        },
        {
          "nct_id": "NCT05346835",
          "title": "Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-cel) Out-of-Specification (OOS) in Patients With Multiple Myeloma",
          "overall_status": "AVAILABLE",
          "phase": null,
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Scientific Affairs, LLC",
          "collaborators": [],
          "interventions": [
            "Cilta-cel OOS Therapy"
          ],
          "last_update": "2025-08-27",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05346835"
        },
        {
          "nct_id": "NCT05767359",
          "title": "CAR- PRISM (PRecision Intervention Smoldering Myeloma): A Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in High-Risk Smoldering Myeloma",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma",
            "Smoldering Multiple Myeloma"
          ],
          "lead_sponsor": "Dana-Farber Cancer Institute",
          "collaborators": [
            "Janssen Research & Development, LLC"
          ],
          "interventions": [
            "Ciltacabtagene Autoleucel",
            "Cyclophosphamide",
            "Fludarabine Phosphate"
          ],
          "last_update": "2025-09-11",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05767359"
        },
        {
          "nct_id": "NCT05347485",
          "title": "A Safety and Efficacy Study of JNJ-68284528 (Ciltacabtagene Autoleucel) Out-of-Specification (OOS) for Commercial Release in Patients With Multiple Myeloma",
          "overall_status": "COMPLETED",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Scientific Affairs, LLC",
          "collaborators": [],
          "interventions": [
            "Cilta-cel",
            "Lymphodepleting Therapy (Cyclophosphamide and Fludarabine)"
          ],
          "last_update": "2025-04-25",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05347485"
        },
        {
          "nct_id": "NCT07093554",
          "title": "Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma",
          "overall_status": "RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Relapse Multiple Myeloma",
            "Refractory Multiple Myeloma"
          ],
          "lead_sponsor": "Medical College of Wisconsin",
          "collaborators": [],
          "interventions": [
            "Talquetamab",
            "Ciltacabtagene Autoleucel"
          ],
          "last_update": "2026-01-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07093554"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok",
      "_ctgov_query_terms": [
        "CARVYKTI (Ciltacabtagene autoleucel)",
        "Ciltacabtagene autoleucel",
        "CARVYKTI"
      ]
    },
    {
      "asset": "ERLEADA (apalutamide)",
      "indication": "Localized Prostate Cancer",
      "phase": null,
      "trial_or_program": "ATLAS",
      "partner": "Regents of California and Memorial Sload Kettering",
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT04662580",
          "title": "A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of ARX517 as Monotherapy and in Combination With Androgen Receptor Pathway Inhibitors in Subjects With Metastatic Prostate Cancer",
          "overall_status": "RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Metastatic Prostate Cancer"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "ARX517",
            "Apalutamide",
            "Abiraterone acetate",
            "Prednisone"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04662580"
        },
        {
          "nct_id": "NCT04325828",
          "title": "An Open-label Phase 2 Study to Evaluate the Efficacy and Safety of Apalutamide in Combination With Gonadotropin-releasing Hormone (GnRH) Agonist in Subjects With Locally Advanced or Recurrent/Metastatic and Androgen Receptor (AR) Expressing Salivary Gland Carcinoma",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Salivary Gland Neoplasms"
          ],
          "lead_sponsor": "Janssen Pharmaceutical K.K.",
          "collaborators": [],
          "interventions": [
            "Apalutamide",
            "GnRH Agonist"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04325828"
        },
        {
          "nct_id": "NCT04108208",
          "title": "A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase IV Study of Apalutamide in Chinese Participants With Non-Metastatic Castration-Resistant Prostate Cancer (NM-CRPC)",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": null,
          "conditions": [
            "Prostatic Neoplasms"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Apalutamide",
            "Placebo",
            "Androgen-deprivation Therapy (ADT)"
          ],
          "last_update": "2025-12-18",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04108208"
        },
        {
          "nct_id": "NCT06019676",
          "title": "Impact of Apalutamide in Metastatic Hormone Sensitive Prostate Cancer Patients, a Multicentre Prospective Observational Study",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": null,
          "conditions": [
            "Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)"
          ],
          "lead_sponsor": "Royal Marsden NHS Foundation Trust",
          "collaborators": [
            "Janssen, LP"
          ],
          "interventions": [],
          "last_update": "2025-09-18",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06019676"
        },
        {
          "nct_id": "NCT02721979",
          "title": "A Phase 2 Study of Apalutamide in Active Surveillance Patients",
          "overall_status": "TERMINATED",
          "phase": "Phase 2",
          "conditions": [
            "Prostate Adenocarcinoma"
          ],
          "lead_sponsor": "University of Washington",
          "collaborators": [
            "Janssen Scientific Affairs, LLC",
            "National Cancer Institute (NCI)"
          ],
          "interventions": [
            "Apalutamide",
            "Laboratory Biomarker Analysis",
            "Quality-of-Life Assessment",
            "Questionnaire Administration"
          ],
          "last_update": "2023-02-09",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT02721979"
        },
        {
          "nct_id": "NCT03365297",
          "title": "Targeted Drug Intervention to Inhibit Cancer Progression in Men on Active Surveillance for Prostate Cancer. Therapeutics in Active Prostate Cancer Surveillance (TAPS01)",
          "overall_status": "COMPLETED",
          "phase": "Phase 2",
          "conditions": [
            "Prostate Cancer"
          ],
          "lead_sponsor": "CCTU- Cancer Theme",
          "collaborators": [
            "Janssen-Cilag Ltd."
          ],
          "interventions": [
            "Apalutamide"
          ],
          "last_update": "2019-11-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT03365297"
        },
        {
          "nct_id": "NCT02257736",
          "title": "A Phase 3 Randomized, Placebo-controlled Double-blind Study of JNJ-56021927 in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Prostatic Neoplasms"
          ],
          "lead_sponsor": "Aragon Pharmaceuticals, Inc.",
          "collaborators": [],
          "interventions": [
            "Apalutamide",
            "Abiraterone acetate",
            "Prednisone",
            "Placebo"
          ],
          "last_update": "2025-12-22",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT02257736"
        },
        {
          "nct_id": "NCT03436654",
          "title": "Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Prostate Cancer"
          ],
          "lead_sponsor": "Memorial Sloan Kettering Cancer Center",
          "collaborators": [
            "Dana-Farber Cancer Institute"
          ],
          "interventions": [
            "Apalutamide",
            "Abiraterone Acetate",
            "Prednisone",
            "Radical Prostatectomy",
            "Extended Pelvic lymphadenectomy",
            "GnRH agonist/antagonist",
            "Stereotactic Body Radiation Therapy"
          ],
          "last_update": "2025-11-28",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT03436654"
        },
        {
          "nct_id": "NCT04585932",
          "title": "Phase 2 Response Evaluation of Finite Systemic Therapy With Advanced Androgen Signaling Inhibition and Radiation Therapy for Oligorecurrent Prostate Cancer (RESTART)",
          "overall_status": "WITHDRAWN",
          "phase": "Phase 2",
          "conditions": [
            "Biochemically Recurrent Prostate Carcinoma",
            "Metastatic Prostate Carcinoma",
            "Oligometastatic Prostate Carcinoma",
            "Stage IV Prostate Cancer AJCC v8",
            "Stage IVA Prostate Cancer AJCC v8",
            "Stage IVB Prostate Cancer AJCC v8"
          ],
          "lead_sponsor": "M.D. Anderson Cancer Center",
          "collaborators": [
            "National Cancer Institute (NCI)"
          ],
          "interventions": [
            "Apalutamide",
            "Degarelix",
            "Leuprolide Acetate",
            "Quality-of-Life Assessment",
            "Questionnaire Administration",
            "Radiation Therapy"
          ],
          "last_update": "2021-01-20",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04585932"
        },
        {
          "nct_id": "NCT04421222",
          "title": "A Phase 1, Open-label Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral EPI-7386 in Patients with Castration-Resistant Prostate Cancer",
          "overall_status": "TERMINATED",
          "phase": "Phase 1",
          "conditions": [
            "Prostate Cancer"
          ],
          "lead_sponsor": "ESSA Pharmaceuticals",
          "collaborators": [],
          "interventions": [
            "EPI-7386 (QD)",
            "EPI-7386 (BID)",
            "Abiraterone acetate",
            "Apalutamide"
          ],
          "last_update": "2025-02-28",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04421222"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok",
      "_ctgov_query_terms": [
        "ERLEADA (apalutamide)",
        "apalutamide",
        "ERLEADA"
      ]
    },
    {
      "asset": "ERLEADA (apalutamide)",
      "indication": "High Risk Prostate Cancer",
      "phase": null,
      "trial_or_program": "PROTEUS",
      "partner": "Regents of California and Memorial Sload Kettering",
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT04662580",
          "title": "A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of ARX517 as Monotherapy and in Combination With Androgen Receptor Pathway Inhibitors in Subjects With Metastatic Prostate Cancer",
          "overall_status": "RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Metastatic Prostate Cancer"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "ARX517",
            "Apalutamide",
            "Abiraterone acetate",
            "Prednisone"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04662580"
        },
        {
          "nct_id": "NCT04325828",
          "title": "An Open-label Phase 2 Study to Evaluate the Efficacy and Safety of Apalutamide in Combination With Gonadotropin-releasing Hormone (GnRH) Agonist in Subjects With Locally Advanced or Recurrent/Metastatic and Androgen Receptor (AR) Expressing Salivary Gland Carcinoma",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Salivary Gland Neoplasms"
          ],
          "lead_sponsor": "Janssen Pharmaceutical K.K.",
          "collaborators": [],
          "interventions": [
            "Apalutamide",
            "GnRH Agonist"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04325828"
        },
        {
          "nct_id": "NCT04108208",
          "title": "A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase IV Study of Apalutamide in Chinese Participants With Non-Metastatic Castration-Resistant Prostate Cancer (NM-CRPC)",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": null,
          "conditions": [
            "Prostatic Neoplasms"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Apalutamide",
            "Placebo",
            "Androgen-deprivation Therapy (ADT)"
          ],
          "last_update": "2025-12-18",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04108208"
        },
        {
          "nct_id": "NCT06019676",
          "title": "Impact of Apalutamide in Metastatic Hormone Sensitive Prostate Cancer Patients, a Multicentre Prospective Observational Study",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": null,
          "conditions": [
            "Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)"
          ],
          "lead_sponsor": "Royal Marsden NHS Foundation Trust",
          "collaborators": [
            "Janssen, LP"
          ],
          "interventions": [],
          "last_update": "2025-09-18",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06019676"
        },
        {
          "nct_id": "NCT02721979",
          "title": "A Phase 2 Study of Apalutamide in Active Surveillance Patients",
          "overall_status": "TERMINATED",
          "phase": "Phase 2",
          "conditions": [
            "Prostate Adenocarcinoma"
          ],
          "lead_sponsor": "University of Washington",
          "collaborators": [
            "Janssen Scientific Affairs, LLC",
            "National Cancer Institute (NCI)"
          ],
          "interventions": [
            "Apalutamide",
            "Laboratory Biomarker Analysis",
            "Quality-of-Life Assessment",
            "Questionnaire Administration"
          ],
          "last_update": "2023-02-09",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT02721979"
        },
        {
          "nct_id": "NCT03365297",
          "title": "Targeted Drug Intervention to Inhibit Cancer Progression in Men on Active Surveillance for Prostate Cancer. Therapeutics in Active Prostate Cancer Surveillance (TAPS01)",
          "overall_status": "COMPLETED",
          "phase": "Phase 2",
          "conditions": [
            "Prostate Cancer"
          ],
          "lead_sponsor": "CCTU- Cancer Theme",
          "collaborators": [
            "Janssen-Cilag Ltd."
          ],
          "interventions": [
            "Apalutamide"
          ],
          "last_update": "2019-11-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT03365297"
        },
        {
          "nct_id": "NCT02257736",
          "title": "A Phase 3 Randomized, Placebo-controlled Double-blind Study of JNJ-56021927 in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Prostatic Neoplasms"
          ],
          "lead_sponsor": "Aragon Pharmaceuticals, Inc.",
          "collaborators": [],
          "interventions": [
            "Apalutamide",
            "Abiraterone acetate",
            "Prednisone",
            "Placebo"
          ],
          "last_update": "2025-12-22",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT02257736"
        },
        {
          "nct_id": "NCT03436654",
          "title": "Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Prostate Cancer"
          ],
          "lead_sponsor": "Memorial Sloan Kettering Cancer Center",
          "collaborators": [
            "Dana-Farber Cancer Institute"
          ],
          "interventions": [
            "Apalutamide",
            "Abiraterone Acetate",
            "Prednisone",
            "Radical Prostatectomy",
            "Extended Pelvic lymphadenectomy",
            "GnRH agonist/antagonist",
            "Stereotactic Body Radiation Therapy"
          ],
          "last_update": "2025-11-28",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT03436654"
        },
        {
          "nct_id": "NCT04585932",
          "title": "Phase 2 Response Evaluation of Finite Systemic Therapy With Advanced Androgen Signaling Inhibition and Radiation Therapy for Oligorecurrent Prostate Cancer (RESTART)",
          "overall_status": "WITHDRAWN",
          "phase": "Phase 2",
          "conditions": [
            "Biochemically Recurrent Prostate Carcinoma",
            "Metastatic Prostate Carcinoma",
            "Oligometastatic Prostate Carcinoma",
            "Stage IV Prostate Cancer AJCC v8",
            "Stage IVA Prostate Cancer AJCC v8",
            "Stage IVB Prostate Cancer AJCC v8"
          ],
          "lead_sponsor": "M.D. Anderson Cancer Center",
          "collaborators": [
            "National Cancer Institute (NCI)"
          ],
          "interventions": [
            "Apalutamide",
            "Degarelix",
            "Leuprolide Acetate",
            "Quality-of-Life Assessment",
            "Questionnaire Administration",
            "Radiation Therapy"
          ],
          "last_update": "2021-01-20",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04585932"
        },
        {
          "nct_id": "NCT04421222",
          "title": "A Phase 1, Open-label Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral EPI-7386 in Patients with Castration-Resistant Prostate Cancer",
          "overall_status": "TERMINATED",
          "phase": "Phase 1",
          "conditions": [
            "Prostate Cancer"
          ],
          "lead_sponsor": "ESSA Pharmaceuticals",
          "collaborators": [],
          "interventions": [
            "EPI-7386 (QD)",
            "EPI-7386 (BID)",
            "Abiraterone acetate",
            "Apalutamide"
          ],
          "last_update": "2025-02-28",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04421222"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok",
      "_ctgov_query_terms": [
        "ERLEADA (apalutamide)",
        "apalutamide",
        "ERLEADA"
      ]
    },
    {
      "asset": "INLEXZO (gemcitabine intravesical system)",
      "indication": "Non Muscle Invasive Bladder Cancer BCG-naïve High Risk",
      "phase": null,
      "trial_or_program": "SunRISe-3",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT04658862",
          "title": "A Phase 3, Multi-center, Randomized Study Evaluating Efficacy of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder Who Are Not Receiving Radical Cystectomy",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Urinary Bladder Neoplasms"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Cetrelimab",
            "TAR-200",
            "Cisplatin",
            "Gemcitabine",
            "Conventional radiation therapy",
            "Hypo-fractioned radiation therapy"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04658862"
        },
        {
          "nct_id": "NCT06319820",
          "title": "A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Non-Muscle Invasive Bladder Cancer"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "TAR-210",
            "Gemcitabine",
            "MMC"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06319820"
        },
        {
          "nct_id": "NCT04640623",
          "title": "Phase 2b Clinical Study Evaluating Efficacy and Safety of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin (BCG) Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Urinary Bladder Neoplasms"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "TAR-200",
            "Cetrelimab"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04640623"
        },
        {
          "nct_id": "NCT06919965",
          "title": "A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Investigator's Choice of Intravesical Chemotherapy in Participants With High-risk Non-muscle-invasive Bladder Cancer With Susceptible FGFR Alterations Who Had Received Intravesical Bacillus Calmette-Guérin (BCG)",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Non-Muscle Invasive Bladder Neoplasms"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "TAR-210",
            "Mitomycin C",
            "Gemcitabine"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06919965"
        },
        {
          "nct_id": "NCT03404791",
          "title": "A Multicenter Study Evaluating Safety and Efficacy of TAR-200 in Subjects With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical Cystectomy",
          "overall_status": "COMPLETED",
          "phase": "Phase 1",
          "conditions": [
            "Urinary Bladder Neoplasms"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "TAR-200"
          ],
          "last_update": "2025-02-04",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT03404791"
        },
        {
          "nct_id": "NCT04172675",
          "title": "A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) and FGFR Mutations or Fusions",
          "overall_status": "COMPLETED",
          "phase": "Phase 2",
          "conditions": [
            "Urinary Bladder Neoplasms"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Erdafitinib",
            "Investigator Choice (Gemcitabine)",
            "Investigator Choice (Mitomycin C)"
          ],
          "last_update": "2025-08-01",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04172675"
        },
        {
          "nct_id": "NCT07000084",
          "title": "GAIN-BCG: Gemcitabine Alternating With INtravesical BCG Randomized Against BCG Alone for Patients With Recurrent High Grade Non-Muscle Invasive Bladder Cancer",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Recurrent Non-Muscle Invasive Bladder Carcinoma",
            "Stage 0a Bladder Cancer AJCC v8",
            "Stage I Bladder Cancer AJCC v8"
          ],
          "lead_sponsor": "Alliance for Clinical Trials in Oncology",
          "collaborators": [
            "National Cancer Institute (NCI)"
          ],
          "interventions": [
            "BCG Solution",
            "Biopsy of Bladder",
            "Cystoscopy",
            "Computed Tomography",
            "Magnetic Resonance Imaging",
            "Biospecimen Collection",
            "Transurethral Resection of Bladder Tumor",
            "Gemcitabine"
          ],
          "last_update": "2026-01-07",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07000084"
        },
        {
          "nct_id": "NCT07307456",
          "title": "A Prospective, Open-label, Single-center Clinical Study Evaluating the Efficacy and Safety of Trastuzumab Combined With BCG Perfusion as an Adjuvant Treatment After TURBT in High-risk/Very High-risk Non-muscle-invasive Bladder Cancer",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Bladder Cancer"
          ],
          "lead_sponsor": "Changhai Hospital",
          "collaborators": [],
          "interventions": [
            "Treatment with toripalimab combined with BCG perfusion following transurethral resection of bladder tumor (TURBT)"
          ],
          "last_update": "2025-12-29",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07307456"
        },
        {
          "nct_id": "NCT05538663",
          "title": "A Randomized Phase III Trial of Intravesical BCG veRsus Intravesical Docetaxel and GEmcitabine Treatment in BCG Naïve High Grade Non-Muscle Invasive Bladder Cancer (BRIDGE)",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Non-muscle-invasive Bladder Cancer"
          ],
          "lead_sponsor": "ECOG-ACRIN Cancer Research Group",
          "collaborators": [
            "National Cancer Institute (NCI)"
          ],
          "interventions": [
            "Gemcitabine",
            "Docetaxel",
            "Bacillus Calmette Guerin"
          ],
          "last_update": "2025-12-30",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05538663"
        },
        {
          "nct_id": "NCT06545955",
          "title": "A Phase 3, Randomised, Multi-center, Open Label Trial to Evaluate the Safety and Efficacy of Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade Bacillus Calmette-Guerin Therapy (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC)",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Non-muscle Invasive Bladder Cancer With Carcinoma in Situ"
          ],
          "lead_sponsor": "Ferring Pharmaceuticals",
          "collaborators": [],
          "interventions": [
            "Nadofaragene Firadenovec",
            "Gemcitabine",
            "Docetaxel",
            "Pembrolizumab"
          ],
          "last_update": "2026-01-06",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06545955"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok",
      "_ctgov_query_terms": [
        "INLEXZO (gemcitabine intravesical system)",
        "gemcitabine intravesical system",
        "INLEXZO"
      ]
    },
    {
      "asset": "INLEXZO (gemcitabine intravesical system)",
      "indication": "High Risk Non Muscle Invasive Bladder Cancer BGC Experienced",
      "phase": null,
      "trial_or_program": "SunRISe-5",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT04658862",
          "title": "A Phase 3, Multi-center, Randomized Study Evaluating Efficacy of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder Who Are Not Receiving Radical Cystectomy",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Urinary Bladder Neoplasms"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Cetrelimab",
            "TAR-200",
            "Cisplatin",
            "Gemcitabine",
            "Conventional radiation therapy",
            "Hypo-fractioned radiation therapy"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04658862"
        },
        {
          "nct_id": "NCT06319820",
          "title": "A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Non-Muscle Invasive Bladder Cancer"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "TAR-210",
            "Gemcitabine",
            "MMC"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06319820"
        },
        {
          "nct_id": "NCT04640623",
          "title": "Phase 2b Clinical Study Evaluating Efficacy and Safety of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin (BCG) Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Urinary Bladder Neoplasms"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "TAR-200",
            "Cetrelimab"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04640623"
        },
        {
          "nct_id": "NCT06919965",
          "title": "A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Investigator's Choice of Intravesical Chemotherapy in Participants With High-risk Non-muscle-invasive Bladder Cancer With Susceptible FGFR Alterations Who Had Received Intravesical Bacillus Calmette-Guérin (BCG)",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Non-Muscle Invasive Bladder Neoplasms"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "TAR-210",
            "Mitomycin C",
            "Gemcitabine"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06919965"
        },
        {
          "nct_id": "NCT03404791",
          "title": "A Multicenter Study Evaluating Safety and Efficacy of TAR-200 in Subjects With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical Cystectomy",
          "overall_status": "COMPLETED",
          "phase": "Phase 1",
          "conditions": [
            "Urinary Bladder Neoplasms"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "TAR-200"
          ],
          "last_update": "2025-02-04",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT03404791"
        },
        {
          "nct_id": "NCT04172675",
          "title": "A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) and FGFR Mutations or Fusions",
          "overall_status": "COMPLETED",
          "phase": "Phase 2",
          "conditions": [
            "Urinary Bladder Neoplasms"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Erdafitinib",
            "Investigator Choice (Gemcitabine)",
            "Investigator Choice (Mitomycin C)"
          ],
          "last_update": "2025-08-01",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04172675"
        },
        {
          "nct_id": "NCT07000084",
          "title": "GAIN-BCG: Gemcitabine Alternating With INtravesical BCG Randomized Against BCG Alone for Patients With Recurrent High Grade Non-Muscle Invasive Bladder Cancer",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Recurrent Non-Muscle Invasive Bladder Carcinoma",
            "Stage 0a Bladder Cancer AJCC v8",
            "Stage I Bladder Cancer AJCC v8"
          ],
          "lead_sponsor": "Alliance for Clinical Trials in Oncology",
          "collaborators": [
            "National Cancer Institute (NCI)"
          ],
          "interventions": [
            "BCG Solution",
            "Biopsy of Bladder",
            "Cystoscopy",
            "Computed Tomography",
            "Magnetic Resonance Imaging",
            "Biospecimen Collection",
            "Transurethral Resection of Bladder Tumor",
            "Gemcitabine"
          ],
          "last_update": "2026-01-07",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07000084"
        },
        {
          "nct_id": "NCT07307456",
          "title": "A Prospective, Open-label, Single-center Clinical Study Evaluating the Efficacy and Safety of Trastuzumab Combined With BCG Perfusion as an Adjuvant Treatment After TURBT in High-risk/Very High-risk Non-muscle-invasive Bladder Cancer",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Bladder Cancer"
          ],
          "lead_sponsor": "Changhai Hospital",
          "collaborators": [],
          "interventions": [
            "Treatment with toripalimab combined with BCG perfusion following transurethral resection of bladder tumor (TURBT)"
          ],
          "last_update": "2025-12-29",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07307456"
        },
        {
          "nct_id": "NCT05538663",
          "title": "A Randomized Phase III Trial of Intravesical BCG veRsus Intravesical Docetaxel and GEmcitabine Treatment in BCG Naïve High Grade Non-Muscle Invasive Bladder Cancer (BRIDGE)",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Non-muscle-invasive Bladder Cancer"
          ],
          "lead_sponsor": "ECOG-ACRIN Cancer Research Group",
          "collaborators": [
            "National Cancer Institute (NCI)"
          ],
          "interventions": [
            "Gemcitabine",
            "Docetaxel",
            "Bacillus Calmette Guerin"
          ],
          "last_update": "2025-12-30",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05538663"
        },
        {
          "nct_id": "NCT06545955",
          "title": "A Phase 3, Randomised, Multi-center, Open Label Trial to Evaluate the Safety and Efficacy of Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade Bacillus Calmette-Guerin Therapy (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC)",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Non-muscle Invasive Bladder Cancer With Carcinoma in Situ"
          ],
          "lead_sponsor": "Ferring Pharmaceuticals",
          "collaborators": [],
          "interventions": [
            "Nadofaragene Firadenovec",
            "Gemcitabine",
            "Docetaxel",
            "Pembrolizumab"
          ],
          "last_update": "2026-01-06",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06545955"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok",
      "_ctgov_query_terms": [
        "INLEXZO (gemcitabine intravesical system)",
        "gemcitabine intravesical system",
        "INLEXZO"
      ]
    },
    {
      "asset": "JNJ-1900 (NBTXR3)",
      "indication": "Head and Neck Cancer",
      "phase": null,
      "trial_or_program": null,
      "partner": "Nanobiotix",
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT04892173",
          "title": "A Phase 3 Study of NBTXR3 Activated by Investigator's Choice of Radiotherapy Alone or Radiotherapy in Combination With Cetuximab for Platinum-based Chemotherapy-Ineligible Elderly Patients With LA-HNSCC",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Locally Advanced Head and Neck Squamous Cell Carcinoma",
            "Aged"
          ],
          "lead_sponsor": "Johnson & Johnson Enterprise Innovation Inc.",
          "collaborators": [],
          "interventions": [
            "JNJ-90301900 (NBTXR3)",
            "Cetuximab",
            "Radiation Therapy"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04892173"
        },
        {
          "nct_id": "NCT04862455",
          "title": "Phase II Study of NBTXR3 Activated by Radiation and Combined With Pembrolizumab for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma With Limited PD-L1 Expression or Refractory to PD-1 Blockade",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Metastatic Head and Neck Squamous Cell Carcinoma",
            "Recurrent Head and Neck Squamous Cell Carcinoma"
          ],
          "lead_sponsor": "M.D. Anderson Cancer Center",
          "collaborators": [],
          "interventions": [
            "Hafnium Oxide-containing Nanoparticles NBTXR3",
            "Hypofractionated Radiation Therapy",
            "Pembrolizumab",
            "Stereotactic Body Radiation Therapy"
          ],
          "last_update": "2025-11-21",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04862455"
        },
        {
          "nct_id": "NCT07224152",
          "title": "NBTXR3 With Radiation Therapy Alone for Locally-advanced Non-small Cell Lung Cancer",
          "overall_status": "NOT_YET_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Locally-Advanced Non-Small Cell Lung Cancer"
          ],
          "lead_sponsor": "M.D. Anderson Cancer Center",
          "collaborators": [
            "Nanobiotix"
          ],
          "interventions": [
            "NBTXR3"
          ],
          "last_update": "2025-12-16",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07224152"
        },
        {
          "nct_id": "NCT07219212",
          "title": "A Study of JNJ-90301900 in Combination With Concurrent Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma",
          "overall_status": "RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Squamous Cell Carcinoma of Head and Neck"
          ],
          "lead_sponsor": "Johnson & Johnson Enterprise Innovation Inc.",
          "collaborators": [],
          "interventions": [
            "JNJ-90301900",
            "Cisplatin",
            "Intensity Modulated Radiation Therapy (IMRT)"
          ],
          "last_update": "2025-12-24",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07219212"
        },
        {
          "nct_id": "NCT02379845",
          "title": "A Multicenter Randomized, Open-Label Phase II/III Study, To Compare The Efficacy Of NBTXR3, Implanted As Intratumor Injection And Activated By Radiotherapy, Versus Radiotherapy Alone In Patients With Locally Advanced Soft Tissue Sarcoma Of The Extremity And Trunk Wall",
          "overall_status": "COMPLETED",
          "phase": "Phase 3",
          "conditions": [
            "Adult Soft Tissue Sarcoma"
          ],
          "lead_sponsor": "Nanobiotix",
          "collaborators": [
            "PharmaEngine"
          ],
          "interventions": [
            "NBTXR3",
            "Radiation therapy"
          ],
          "last_update": "2021-04-06",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT02379845"
        },
        {
          "nct_id": "NCT01433068",
          "title": "An Open-Label, Single Arm, Feasibility And Safety Phase I Study With NBTXR3 Intratumor Implantation (By Injection) And Activated By External Beam Radiation Therapy In Patients With Soft Tissue Sarcoma Of The Extremity And Trunk Wall",
          "overall_status": "COMPLETED",
          "phase": "Phase 1",
          "conditions": [
            "Adult Soft Tissue Sarcoma"
          ],
          "lead_sponsor": "Nanobiotix",
          "collaborators": [],
          "interventions": [
            "NBTXR3"
          ],
          "last_update": "2020-10-06",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT01433068"
        },
        {
          "nct_id": "NCT05039632",
          "title": "Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Advanced Malignant Solid Neoplasm",
            "Metastatic Malignant Neoplasm in the Liver",
            "Metastatic Malignant Neoplasm in the Lung",
            "Metastatic Malignant Solid Neoplasm"
          ],
          "lead_sponsor": "M.D. Anderson Cancer Center",
          "collaborators": [
            "National Cancer Institute (NCI)"
          ],
          "interventions": [
            "Hafnium Oxide-containing Nanoparticles NBTXR3",
            "Radiation Therapy",
            "Radiation Therapy"
          ],
          "last_update": "2025-11-06",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05039632"
        },
        {
          "nct_id": "NCT02805894",
          "title": "A Phase I-II Dose-escalation Study of NBTXR3 Activated by EBRT or EBRT With Brachytherapy in Patients With Newly Diagnosed Unfavorable Intermediate or High Risk Prostate Adenocarcinoma Treated With Androgen Deprivation",
          "overall_status": "TERMINATED",
          "phase": "Phase 2",
          "conditions": [
            "Prostate Cancer"
          ],
          "lead_sponsor": "Nanobiotix",
          "collaborators": [],
          "interventions": [
            "NBTXR3 activated by IMRT only",
            "NBTXR3 activated by Brachytherapy & IMRT"
          ],
          "last_update": "2021-05-10",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT02805894"
        },
        {
          "nct_id": "NCT03589339",
          "title": "A Phase I Dose Escalation / Dose Expansion Study of NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Radiotherapy",
            "Immunotherapy",
            "Microsatellite Instability-High Solid Malignant Tumour",
            "Metastasis From Malignant Tumor of Liver",
            "Squamous Cell Carcinoma of Head and Neck",
            "Metastasis From Malignant Tumor of Cervix",
            "Metastatic Renal Cell Carcinoma",
            "Metastasis From Malignant Melanoma of Skin (Disorder)",
            "Metastatic Triple-Negative Breast Carcinoma",
            "Metastatic NSCLC"
          ],
          "lead_sponsor": "Nanobiotix",
          "collaborators": [],
          "interventions": [
            "NBTXR3",
            "SABR",
            "Nivolumab",
            "Pembrolizumab"
          ],
          "last_update": "2025-10-24",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT03589339"
        },
        {
          "nct_id": "NCT02721056",
          "title": "A Phase I-II Study of NBTXR3 Activated by Sterostatic Body Radiation Therapy (SBRT) In the Treatment of Liver Cancers",
          "overall_status": "TERMINATED",
          "phase": "Phase 2",
          "conditions": [
            "Liver Cancer"
          ],
          "lead_sponsor": "Nanobiotix",
          "collaborators": [],
          "interventions": [
            "NBTXR3, IL or IA injection + SBRT"
          ],
          "last_update": "2021-05-10",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT02721056"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok",
      "_ctgov_query_terms": [
        "JNJ-1900 (NBTXR3)",
        "NBTXR3",
        "JNJ-1900"
      ]
    },
    {
      "asset": "pasritamig",
      "indication": "Prostate Cancer",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT07319871",
          "title": "A Phase 1b Study of Pasritamig (JNJ-78278343), a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination With JNJ-86974680, an A2a Receptor (A2aR) Antagonist, for Prostate Cancer",
          "overall_status": "RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Prostatic Neoplasms"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Pasritamig",
            "JNJ-86974680"
          ],
          "last_update": "2026-01-06",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07319871"
        },
        {
          "nct_id": "NCT07225946",
          "title": "A Phase 3 Randomized, Open-label Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2, With Docetaxel Versus Docetaxel for Metastatic Castration-resistant Prostate Cancer",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Prostatic Neoplasms, Castration-Resistant"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Pasritamig",
            "Docetaxel",
            "Prednisone"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07225946"
        },
        {
          "nct_id": "NCT07164443",
          "title": "A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T Cell Redirecting Agent Targeting Human Kallikrein 2, + Best Supportive Care Versus Best Supportive Care for Metastatic Castration-resistant Prostate Cancer",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Metastatic Castration-resistant Prostate Neoplasms"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Pasritamig",
            "Placebo",
            "Best Supportive Care (BSC)"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07164443"
        },
        {
          "nct_id": "NCT06095089",
          "title": "A Phase 1 Study of JNJ-87189401 (PSMA-CD28 Bispecific Antibody) Combined With JNJ-78278343 (KLK2-CD3 Bispecific Antibody) for Advanced Prostate Cancer",
          "overall_status": "RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Advanced Prostate Cancer"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "JNJ-78278343",
            "JNJ-87189401"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06095089"
        },
        {
          "nct_id": "NCT07082920",
          "title": "A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination With JNJ-95298177, an Antibody Drug Conjugate Targeting Prostate Specific Membrane Antigen, for Prostate Cancer",
          "overall_status": "RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Prostatic Neoplasms"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "JNJ-78278343",
            "JNJ-95298177"
          ],
          "last_update": "2025-12-17",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07082920"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok",
      "_ctgov_query_terms": [
        "pasritamig"
      ]
    },
    {
      "asset": "RYBREVANT (amivantamab)",
      "indication": "Colorectal Cancer",
      "phase": null,
      "trial_or_program": "ORIGAMI-2",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT05379595",
          "title": "A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Advanced or Metastatic Colorectal Cancer"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Amivantamab IV",
            "Fluorouracil",
            "Leucovorin",
            "Oxaliplatin",
            "Irinotecan",
            "Amivantamab"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05379595"
        },
        {
          "nct_id": "NCT07276399",
          "title": "A Phase 3, Randomized, Open-Label, Multicenter Study of Amivantamab in Addition to Carboplatin and Pembrolizumab, Compared to Standard of Care Platinum and Pembrolizumab and 5-FU, in Participants With Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Squamous Cell Carcinoma of Head and Neck"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Amivantamab",
            "Pembrolizumab",
            "Carboplatin",
            "5-Flurouracil",
            "Cisplatin"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07276399"
        },
        {
          "nct_id": "NCT07227025",
          "title": "A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Olomorasib Combination Therapy in Metastatic Non-small Cell Lung Cancer",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Carcinoma, Non-Small-Cell Lung"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Amivantamab",
            "Olomorasib"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07227025"
        },
        {
          "nct_id": "NCT04988295",
          "title": "A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Carcinoma, Non-Small-Cell Lung"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Lazertinib",
            "Amivantamab",
            "Pemetrexed",
            "Carboplatin"
          ],
          "last_update": "2025-12-23",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04988295"
        },
        {
          "nct_id": "NCT04606381",
          "title": "An Open-label, Multicenter, Dose Escalation Phase 1b Study to Assess the Safety and Pharmacokinetics of Subcutaneous Delivery of Amivantamab, a Human Bispecific EGFR and cMet Antibody for the Treatment of Advanced Solid Malignancies",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Advanced Solid Malignancies"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Ami-LC-MD",
            "Ami-LC",
            "Ami-HC",
            "Ami-HC-CF",
            "Lazertinib"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04606381"
        },
        {
          "nct_id": "NCT04538664",
          "title": "A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Patients With EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Carcinoma, Non-Small-Cell Lung"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Amivantamab",
            "Pemetrexed",
            "Carboplatin",
            "Pemetrexed"
          ],
          "last_update": "2025-12-23",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04538664"
        },
        {
          "nct_id": "NCT04077463",
          "title": "An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ-73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non-Small Cell Lung Cancer",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Carcinoma, Non-Small-Cell Lung"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Lazertinib",
            "Amivantamab",
            "Carboplatin",
            "Pemetrexed"
          ],
          "last_update": "2025-12-24",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04077463"
        },
        {
          "nct_id": "NCT06532032",
          "title": "A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Docetaxel Combination Therapy in Metastatic Non-small Cell Lung Cancer",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Carcinoma, Non-Small-Cell Lung"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Amivantamab",
            "Docetaxel"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06532032"
        },
        {
          "nct_id": "NCT02609776",
          "title": "A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects With Advanced Non-Small Cell Lung Cancer",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Non-Small-Cell Lung Cancer"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Amivantamab",
            "Amivantamab",
            "Lazertinib",
            "Carboplatin",
            "Pemetrexed"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT02609776"
        },
        {
          "nct_id": "NCT04487080",
          "title": "A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer.",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Carcinoma, Non-Small-Cell Lung"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Amivantamab",
            "Osimertinib",
            "Lazertinib",
            "Placebo"
          ],
          "last_update": "2025-12-23",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04487080"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok",
      "_ctgov_query_terms": [
        "RYBREVANT (amivantamab)",
        "amivantamab",
        "RYBREVANT"
      ]
    },
    {
      "asset": "RYBREVANT (amivantamab)",
      "indication": "Colorectal Cancer 2L",
      "phase": null,
      "trial_or_program": "ORIGAMI-3",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT05379595",
          "title": "A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Advanced or Metastatic Colorectal Cancer"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Amivantamab IV",
            "Fluorouracil",
            "Leucovorin",
            "Oxaliplatin",
            "Irinotecan",
            "Amivantamab"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05379595"
        },
        {
          "nct_id": "NCT07276399",
          "title": "A Phase 3, Randomized, Open-Label, Multicenter Study of Amivantamab in Addition to Carboplatin and Pembrolizumab, Compared to Standard of Care Platinum and Pembrolizumab and 5-FU, in Participants With Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Squamous Cell Carcinoma of Head and Neck"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Amivantamab",
            "Pembrolizumab",
            "Carboplatin",
            "5-Flurouracil",
            "Cisplatin"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07276399"
        },
        {
          "nct_id": "NCT07227025",
          "title": "A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Olomorasib Combination Therapy in Metastatic Non-small Cell Lung Cancer",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Carcinoma, Non-Small-Cell Lung"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Amivantamab",
            "Olomorasib"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07227025"
        },
        {
          "nct_id": "NCT04988295",
          "title": "A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Carcinoma, Non-Small-Cell Lung"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Lazertinib",
            "Amivantamab",
            "Pemetrexed",
            "Carboplatin"
          ],
          "last_update": "2025-12-23",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04988295"
        },
        {
          "nct_id": "NCT04606381",
          "title": "An Open-label, Multicenter, Dose Escalation Phase 1b Study to Assess the Safety and Pharmacokinetics of Subcutaneous Delivery of Amivantamab, a Human Bispecific EGFR and cMet Antibody for the Treatment of Advanced Solid Malignancies",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Advanced Solid Malignancies"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Ami-LC-MD",
            "Ami-LC",
            "Ami-HC",
            "Ami-HC-CF",
            "Lazertinib"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04606381"
        },
        {
          "nct_id": "NCT04538664",
          "title": "A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Patients With EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Carcinoma, Non-Small-Cell Lung"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Amivantamab",
            "Pemetrexed",
            "Carboplatin",
            "Pemetrexed"
          ],
          "last_update": "2025-12-23",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04538664"
        },
        {
          "nct_id": "NCT04077463",
          "title": "An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ-73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non-Small Cell Lung Cancer",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Carcinoma, Non-Small-Cell Lung"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Lazertinib",
            "Amivantamab",
            "Carboplatin",
            "Pemetrexed"
          ],
          "last_update": "2025-12-24",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04077463"
        },
        {
          "nct_id": "NCT06532032",
          "title": "A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Docetaxel Combination Therapy in Metastatic Non-small Cell Lung Cancer",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Carcinoma, Non-Small-Cell Lung"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Amivantamab",
            "Docetaxel"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06532032"
        },
        {
          "nct_id": "NCT02609776",
          "title": "A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects With Advanced Non-Small Cell Lung Cancer",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Non-Small-Cell Lung Cancer"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Amivantamab",
            "Amivantamab",
            "Lazertinib",
            "Carboplatin",
            "Pemetrexed"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT02609776"
        },
        {
          "nct_id": "NCT04487080",
          "title": "A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer.",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Carcinoma, Non-Small-Cell Lung"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Amivantamab",
            "Osimertinib",
            "Lazertinib",
            "Placebo"
          ],
          "last_update": "2025-12-23",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04487080"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok",
      "_ctgov_query_terms": [
        "RYBREVANT (amivantamab)",
        "amivantamab",
        "RYBREVANT"
      ]
    },
    {
      "asset": "TALVEY + TECVAYLI",
      "indication": "Relapsed Refractory Multiple Myeloma CD38 exposed",
      "phase": null,
      "trial_or_program": "MonumenTAL-6",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT06285318",
          "title": "A Retrospective, Multicountry Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma Treated With T-cell Redirectors Outside of Clinical Trials",
          "overall_status": "RECRUITING",
          "phase": null,
          "conditions": [
            "Relapsed/Refractory Multiple Myeloma (RRMM)"
          ],
          "lead_sponsor": "Janssen-Cilag Ltd.",
          "collaborators": [],
          "interventions": [
            "Teclistamab",
            "Talquetamab"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06285318"
        },
        {
          "nct_id": "NCT06208150",
          "title": "A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants With Relapsed or Refractory Myeloma Who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Talquetamab",
            "Pomalidomide",
            "Teclistamab",
            "Elotuzumab",
            "Dexamethasone",
            "Bortezomib"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06208150"
        },
        {
          "nct_id": "NCT05972135",
          "title": "Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "SCRI Development Innovations, LLC",
          "collaborators": [
            "Johnson & Johnson"
          ],
          "interventions": [
            "Teclistamab",
            "Talquetamab",
            "Tocilizumab"
          ],
          "last_update": "2025-10-29",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05972135"
        },
        {
          "nct_id": "NCT07029776",
          "title": "A Phase 2 Study Exploring the Use of Bispecific Antibodies to Improve Progression Free Survival in Patients With High-Risk Newly Diagnosed Multiple Myeloma (MMulti-Immune HR)",
          "overall_status": "NOT_YET_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma (MM)"
          ],
          "lead_sponsor": "University of Arkansas",
          "collaborators": [
            "Janssen Research & Development, LLC"
          ],
          "interventions": [
            "teclistamab+daratumumab followed by talquetamab+daratumumab followed by duration treatment with daratumumab and lenalidomide extended/maintenance",
            "melphalan (MEL)-based hematopietic stem cell transplantation (HSCT) followed by drug therapy"
          ],
          "last_update": "2025-11-06",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07029776"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok",
      "_ctgov_query_terms": [
        "TALVEY + TECVAYLI"
      ]
    },
    {
      "asset": "TALVEY (talquetamab)",
      "indication": "Relapsed Refractory Multiple Myeloma CD38 exposed",
      "phase": null,
      "trial_or_program": "MonumenTAL-6",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT06285318",
          "title": "A Retrospective, Multicountry Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma Treated With T-cell Redirectors Outside of Clinical Trials",
          "overall_status": "RECRUITING",
          "phase": null,
          "conditions": [
            "Relapsed/Refractory Multiple Myeloma (RRMM)"
          ],
          "lead_sponsor": "Janssen-Cilag Ltd.",
          "collaborators": [],
          "interventions": [
            "Teclistamab",
            "Talquetamab"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06285318"
        },
        {
          "nct_id": "NCT06208150",
          "title": "A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants With Relapsed or Refractory Myeloma Who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Talquetamab",
            "Pomalidomide",
            "Teclistamab",
            "Elotuzumab",
            "Dexamethasone",
            "Bortezomib"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06208150"
        },
        {
          "nct_id": "NCT05050097",
          "title": "A Multi-arm Phase 1b Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Talquetamab",
            "Carfilzomib",
            "Daratumumab SC",
            "Lenalidomide",
            "Pomalidomide"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05050097"
        },
        {
          "nct_id": "NCT04108195",
          "title": "A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Subjects With Multiple Myeloma",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Daratumumab",
            "Talquetamab",
            "Teclistamab",
            "Pomalidomide"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04108195"
        },
        {
          "nct_id": "NCT05455320",
          "title": "A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination With Daratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone (DPd), in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received at Least 1 Prior Line of Therapy",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Relapsed or Refractory Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Talquetamab",
            "Daratumumab",
            "Pomalidomide",
            "Dexamethasone"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05455320"
        },
        {
          "nct_id": "NCT05503550",
          "title": "Pre-Approval Access Single Patient Request Treatment for Talquetamab for Treating Physician Use in Relapsed or Refractory Multiple Myeloma",
          "overall_status": "NO_LONGER_AVAILABLE",
          "phase": null,
          "conditions": [
            "Relapsed or Refractory Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Talquetamab"
          ],
          "last_update": "2025-12-16",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05503550"
        },
        {
          "nct_id": "NCT04586426",
          "title": "A Phase 1b/2 Dose Escalation and Expansion Study of the Combination of the Bispecific T Cell Redirection Antibodies Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Talquetamab",
            "Teclistamab"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04586426"
        },
        {
          "nct_id": "NCT06500884",
          "title": "A Phase 2, Open-label, Randomized Study to Evaluate Prophylactic Interventions on Talquetamab-related Oral Toxicity",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Relapse Multiple Myeloma",
            "Refractory Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Talquetamab",
            "Prophylaxis A",
            "Prophylaxis B",
            "Prophylaxis C"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06500884"
        },
        {
          "nct_id": "NCT03399799",
          "title": "A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a Humanized GPRC5D x CD3 Bispecific Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Hematological Malignancies"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Talquetamab"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT03399799"
        },
        {
          "nct_id": "NCT05972135",
          "title": "Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "SCRI Development Innovations, LLC",
          "collaborators": [
            "Johnson & Johnson"
          ],
          "interventions": [
            "Teclistamab",
            "Talquetamab",
            "Tocilizumab"
          ],
          "last_update": "2025-10-29",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05972135"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok",
      "_ctgov_query_terms": [
        "TALVEY (talquetamab)",
        "talquetamab",
        "TALVEY"
      ]
    },
    {
      "asset": "TALVEY (talquetamab)",
      "indication": "Relapsed Refractory Multiple Myeloma A-CD38 Naïve",
      "phase": null,
      "trial_or_program": "MonumenTAL-3",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT06285318",
          "title": "A Retrospective, Multicountry Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma Treated With T-cell Redirectors Outside of Clinical Trials",
          "overall_status": "RECRUITING",
          "phase": null,
          "conditions": [
            "Relapsed/Refractory Multiple Myeloma (RRMM)"
          ],
          "lead_sponsor": "Janssen-Cilag Ltd.",
          "collaborators": [],
          "interventions": [
            "Teclistamab",
            "Talquetamab"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06285318"
        },
        {
          "nct_id": "NCT06208150",
          "title": "A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants With Relapsed or Refractory Myeloma Who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Talquetamab",
            "Pomalidomide",
            "Teclistamab",
            "Elotuzumab",
            "Dexamethasone",
            "Bortezomib"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06208150"
        },
        {
          "nct_id": "NCT05050097",
          "title": "A Multi-arm Phase 1b Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Talquetamab",
            "Carfilzomib",
            "Daratumumab SC",
            "Lenalidomide",
            "Pomalidomide"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05050097"
        },
        {
          "nct_id": "NCT04108195",
          "title": "A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Subjects With Multiple Myeloma",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Daratumumab",
            "Talquetamab",
            "Teclistamab",
            "Pomalidomide"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04108195"
        },
        {
          "nct_id": "NCT05455320",
          "title": "A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination With Daratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone (DPd), in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received at Least 1 Prior Line of Therapy",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Relapsed or Refractory Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Talquetamab",
            "Daratumumab",
            "Pomalidomide",
            "Dexamethasone"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05455320"
        },
        {
          "nct_id": "NCT05503550",
          "title": "Pre-Approval Access Single Patient Request Treatment for Talquetamab for Treating Physician Use in Relapsed or Refractory Multiple Myeloma",
          "overall_status": "NO_LONGER_AVAILABLE",
          "phase": null,
          "conditions": [
            "Relapsed or Refractory Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Talquetamab"
          ],
          "last_update": "2025-12-16",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05503550"
        },
        {
          "nct_id": "NCT04586426",
          "title": "A Phase 1b/2 Dose Escalation and Expansion Study of the Combination of the Bispecific T Cell Redirection Antibodies Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Talquetamab",
            "Teclistamab"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04586426"
        },
        {
          "nct_id": "NCT06500884",
          "title": "A Phase 2, Open-label, Randomized Study to Evaluate Prophylactic Interventions on Talquetamab-related Oral Toxicity",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Relapse Multiple Myeloma",
            "Refractory Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Talquetamab",
            "Prophylaxis A",
            "Prophylaxis B",
            "Prophylaxis C"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06500884"
        },
        {
          "nct_id": "NCT03399799",
          "title": "A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a Humanized GPRC5D x CD3 Bispecific Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Hematological Malignancies"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Talquetamab"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT03399799"
        },
        {
          "nct_id": "NCT05972135",
          "title": "Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "SCRI Development Innovations, LLC",
          "collaborators": [
            "Johnson & Johnson"
          ],
          "interventions": [
            "Teclistamab",
            "Talquetamab",
            "Tocilizumab"
          ],
          "last_update": "2025-10-29",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05972135"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok",
      "_ctgov_query_terms": [
        "TALVEY (talquetamab)",
        "talquetamab",
        "TALVEY"
      ]
    },
    {
      "asset": "TAR-210 (RIS/erdafitinib)",
      "indication": "Intravesical Delivery System for Localized Bladder Cancer",
      "phase": null,
      "trial_or_program": "MoonRISe-1",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT03390504",
          "title": "A Phase 3 Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects With Advanced Urothelial Cancer and Selected FGFR Gene Aberrations",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Urothelial Cancer"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Erdafitinib",
            "Vinflunine",
            "Docetaxel",
            "Pembrolizumab",
            "Fibroblast Growth Factor Receptor inhibitor Clinical Trial Assay (FGFRi CTA)"
          ],
          "last_update": "2025-12-22",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT03390504"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok",
      "_ctgov_query_terms": [
        "TAR-210 (RIS/erdafitinib)",
        "RIS/erdafitinib",
        "TAR-210 (RIS",
        "erdafitinib)"
      ]
    },
    {
      "asset": "TECVAYLI (teclistamab)",
      "indication": "Multiple Myeloma 1-3PLs",
      "phase": null,
      "trial_or_program": "MajesTEC-3",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT05243797",
          "title": "Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation - MajesTEC-4",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "European Myeloma Network B.V.",
          "collaborators": [
            "Janssen Pharmaceutica"
          ],
          "interventions": [
            "Teclistamab",
            "Lenalidomide"
          ],
          "last_update": "2025-12-30",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05243797"
        },
        {
          "nct_id": "NCT06285318",
          "title": "A Retrospective, Multicountry Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma Treated With T-cell Redirectors Outside of Clinical Trials",
          "overall_status": "RECRUITING",
          "phase": null,
          "conditions": [
            "Relapsed/Refractory Multiple Myeloma (RRMM)"
          ],
          "lead_sponsor": "Janssen-Cilag Ltd.",
          "collaborators": [],
          "interventions": [
            "Teclistamab",
            "Talquetamab"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06285318"
        },
        {
          "nct_id": "NCT06251076",
          "title": "Outpatient-based Teclistamab Step-up Dosing in Patients With Relapsed/Refractory Multiple Myeloma: Process Development in Academic and Community Centres, and Evaluating Impact on Caregiver Burden",
          "overall_status": "RECRUITING",
          "phase": null,
          "conditions": [
            "Multiple Myeloma",
            "Relapsed Cancer",
            "Refractory Cancer"
          ],
          "lead_sponsor": "University Health Network, Toronto",
          "collaborators": [
            "Janssen Inc."
          ],
          "interventions": [
            "Teclistamab",
            "Tocilizumab"
          ],
          "last_update": "2025-12-10",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06251076"
        },
        {
          "nct_id": "NCT06208150",
          "title": "A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants With Relapsed or Refractory Myeloma Who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Talquetamab",
            "Pomalidomide",
            "Teclistamab",
            "Elotuzumab",
            "Dexamethasone",
            "Bortezomib"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06208150"
        },
        {
          "nct_id": "NCT07110844",
          "title": "A Phase 2 Clinical Trial of Teclistamab and Daratumumab in Previously Untreated AL Amyloidosis",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Amyloid Light-chain Amyloidosis"
          ],
          "lead_sponsor": "Suzanne Lentzsch, MD",
          "collaborators": [
            "Janssen Pharmaceuticals"
          ],
          "interventions": [
            "Teclistamab",
            "Daratumumab and Hyaluronidase-fihj"
          ],
          "last_update": "2025-11-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07110844"
        },
        {
          "nct_id": "NCT04696809",
          "title": "A Phase 1/2 Study of JNJ-64007957, a Humanized BCMA * CD3 Bispecific Antibody in Japanese Patients With Relapsed or Refractory Multiple Myeloma",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Hematologic Malignancies"
          ],
          "lead_sponsor": "Janssen Pharmaceutical K.K.",
          "collaborators": [],
          "interventions": [
            "Teclistamab"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04696809"
        },
        {
          "nct_id": "NCT04557098",
          "title": "A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Teclistamab, a Humanized BCMA x CD3 Bispecific Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Hematological Malignancies"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Teclistamab"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04557098"
        },
        {
          "nct_id": "NCT07105059",
          "title": "Teclistamab and Mezigdomide for Relapsed/Refractory Multiple Myeloma",
          "overall_status": "RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Memorial Sloan Kettering Cancer Center",
          "collaborators": [
            "Bristol-Myers Squibb",
            "Johnson & Johnson"
          ],
          "interventions": [
            "Teclistamab",
            "Mezigdomide"
          ],
          "last_update": "2025-11-28",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07105059"
        },
        {
          "nct_id": "NCT07030517",
          "title": "An Open Label, Multicenter, Phase IV Study of Teclistamab to Evaluate Its Safety in Indian Participants With Relapsed and Refractory Multiple Myeloma Who Have Previously Received at Least 3 Prior Lines of Therapy Including an Immunomodulatory Agent, a Proteasome Inhibitor and an Anti-CD38 Antibody and Have Demonstrated Disease Progression on the Last Therapy",
          "overall_status": "RECRUITING",
          "phase": null,
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Johnson & Johnson Private Limited",
          "collaborators": [],
          "interventions": [
            "Teclistamab"
          ],
          "last_update": "2025-12-24",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07030517"
        },
        {
          "nct_id": "NCT04108195",
          "title": "A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Subjects With Multiple Myeloma",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Daratumumab",
            "Talquetamab",
            "Teclistamab",
            "Pomalidomide"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04108195"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok",
      "_ctgov_query_terms": [
        "TECVAYLI (teclistamab)",
        "teclistamab",
        "TECVAYLI"
      ]
    },
    {
      "asset": "TECVAYLI (teclistamab)",
      "indication": "TE NDMM maintenance",
      "phase": null,
      "trial_or_program": "MajesTEC-4",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT05243797",
          "title": "Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation - MajesTEC-4",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "European Myeloma Network B.V.",
          "collaborators": [
            "Janssen Pharmaceutica"
          ],
          "interventions": [
            "Teclistamab",
            "Lenalidomide"
          ],
          "last_update": "2025-12-30",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05243797"
        },
        {
          "nct_id": "NCT06285318",
          "title": "A Retrospective, Multicountry Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma Treated With T-cell Redirectors Outside of Clinical Trials",
          "overall_status": "RECRUITING",
          "phase": null,
          "conditions": [
            "Relapsed/Refractory Multiple Myeloma (RRMM)"
          ],
          "lead_sponsor": "Janssen-Cilag Ltd.",
          "collaborators": [],
          "interventions": [
            "Teclistamab",
            "Talquetamab"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06285318"
        },
        {
          "nct_id": "NCT06251076",
          "title": "Outpatient-based Teclistamab Step-up Dosing in Patients With Relapsed/Refractory Multiple Myeloma: Process Development in Academic and Community Centres, and Evaluating Impact on Caregiver Burden",
          "overall_status": "RECRUITING",
          "phase": null,
          "conditions": [
            "Multiple Myeloma",
            "Relapsed Cancer",
            "Refractory Cancer"
          ],
          "lead_sponsor": "University Health Network, Toronto",
          "collaborators": [
            "Janssen Inc."
          ],
          "interventions": [
            "Teclistamab",
            "Tocilizumab"
          ],
          "last_update": "2025-12-10",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06251076"
        },
        {
          "nct_id": "NCT06208150",
          "title": "A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants With Relapsed or Refractory Myeloma Who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Talquetamab",
            "Pomalidomide",
            "Teclistamab",
            "Elotuzumab",
            "Dexamethasone",
            "Bortezomib"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06208150"
        },
        {
          "nct_id": "NCT07110844",
          "title": "A Phase 2 Clinical Trial of Teclistamab and Daratumumab in Previously Untreated AL Amyloidosis",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Amyloid Light-chain Amyloidosis"
          ],
          "lead_sponsor": "Suzanne Lentzsch, MD",
          "collaborators": [
            "Janssen Pharmaceuticals"
          ],
          "interventions": [
            "Teclistamab",
            "Daratumumab and Hyaluronidase-fihj"
          ],
          "last_update": "2025-11-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07110844"
        },
        {
          "nct_id": "NCT04696809",
          "title": "A Phase 1/2 Study of JNJ-64007957, a Humanized BCMA * CD3 Bispecific Antibody in Japanese Patients With Relapsed or Refractory Multiple Myeloma",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Hematologic Malignancies"
          ],
          "lead_sponsor": "Janssen Pharmaceutical K.K.",
          "collaborators": [],
          "interventions": [
            "Teclistamab"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04696809"
        },
        {
          "nct_id": "NCT04557098",
          "title": "A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Teclistamab, a Humanized BCMA x CD3 Bispecific Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Hematological Malignancies"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Teclistamab"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04557098"
        },
        {
          "nct_id": "NCT07105059",
          "title": "Teclistamab and Mezigdomide for Relapsed/Refractory Multiple Myeloma",
          "overall_status": "RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Memorial Sloan Kettering Cancer Center",
          "collaborators": [
            "Bristol-Myers Squibb",
            "Johnson & Johnson"
          ],
          "interventions": [
            "Teclistamab",
            "Mezigdomide"
          ],
          "last_update": "2025-11-28",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07105059"
        },
        {
          "nct_id": "NCT07030517",
          "title": "An Open Label, Multicenter, Phase IV Study of Teclistamab to Evaluate Its Safety in Indian Participants With Relapsed and Refractory Multiple Myeloma Who Have Previously Received at Least 3 Prior Lines of Therapy Including an Immunomodulatory Agent, a Proteasome Inhibitor and an Anti-CD38 Antibody and Have Demonstrated Disease Progression on the Last Therapy",
          "overall_status": "RECRUITING",
          "phase": null,
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Johnson & Johnson Private Limited",
          "collaborators": [],
          "interventions": [
            "Teclistamab"
          ],
          "last_update": "2025-12-24",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07030517"
        },
        {
          "nct_id": "NCT04108195",
          "title": "A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Subjects With Multiple Myeloma",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Daratumumab",
            "Talquetamab",
            "Teclistamab",
            "Pomalidomide"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04108195"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok",
      "_ctgov_query_terms": [
        "TECVAYLI (teclistamab)",
        "teclistamab",
        "TECVAYLI"
      ]
    },
    {
      "asset": "TECVAYLI (teclistamab)",
      "indication": "TIE NDMM in combination with DR",
      "phase": null,
      "trial_or_program": "MajesTEC-7",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT05243797",
          "title": "Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation - MajesTEC-4",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "European Myeloma Network B.V.",
          "collaborators": [
            "Janssen Pharmaceutica"
          ],
          "interventions": [
            "Teclistamab",
            "Lenalidomide"
          ],
          "last_update": "2025-12-30",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05243797"
        },
        {
          "nct_id": "NCT06285318",
          "title": "A Retrospective, Multicountry Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma Treated With T-cell Redirectors Outside of Clinical Trials",
          "overall_status": "RECRUITING",
          "phase": null,
          "conditions": [
            "Relapsed/Refractory Multiple Myeloma (RRMM)"
          ],
          "lead_sponsor": "Janssen-Cilag Ltd.",
          "collaborators": [],
          "interventions": [
            "Teclistamab",
            "Talquetamab"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06285318"
        },
        {
          "nct_id": "NCT06251076",
          "title": "Outpatient-based Teclistamab Step-up Dosing in Patients With Relapsed/Refractory Multiple Myeloma: Process Development in Academic and Community Centres, and Evaluating Impact on Caregiver Burden",
          "overall_status": "RECRUITING",
          "phase": null,
          "conditions": [
            "Multiple Myeloma",
            "Relapsed Cancer",
            "Refractory Cancer"
          ],
          "lead_sponsor": "University Health Network, Toronto",
          "collaborators": [
            "Janssen Inc."
          ],
          "interventions": [
            "Teclistamab",
            "Tocilizumab"
          ],
          "last_update": "2025-12-10",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06251076"
        },
        {
          "nct_id": "NCT06208150",
          "title": "A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants With Relapsed or Refractory Myeloma Who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Talquetamab",
            "Pomalidomide",
            "Teclistamab",
            "Elotuzumab",
            "Dexamethasone",
            "Bortezomib"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06208150"
        },
        {
          "nct_id": "NCT07110844",
          "title": "A Phase 2 Clinical Trial of Teclistamab and Daratumumab in Previously Untreated AL Amyloidosis",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Amyloid Light-chain Amyloidosis"
          ],
          "lead_sponsor": "Suzanne Lentzsch, MD",
          "collaborators": [
            "Janssen Pharmaceuticals"
          ],
          "interventions": [
            "Teclistamab",
            "Daratumumab and Hyaluronidase-fihj"
          ],
          "last_update": "2025-11-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07110844"
        },
        {
          "nct_id": "NCT04696809",
          "title": "A Phase 1/2 Study of JNJ-64007957, a Humanized BCMA * CD3 Bispecific Antibody in Japanese Patients With Relapsed or Refractory Multiple Myeloma",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Hematologic Malignancies"
          ],
          "lead_sponsor": "Janssen Pharmaceutical K.K.",
          "collaborators": [],
          "interventions": [
            "Teclistamab"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04696809"
        },
        {
          "nct_id": "NCT04557098",
          "title": "A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Teclistamab, a Humanized BCMA x CD3 Bispecific Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Hematological Malignancies"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Teclistamab"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04557098"
        },
        {
          "nct_id": "NCT07105059",
          "title": "Teclistamab and Mezigdomide for Relapsed/Refractory Multiple Myeloma",
          "overall_status": "RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Memorial Sloan Kettering Cancer Center",
          "collaborators": [
            "Bristol-Myers Squibb",
            "Johnson & Johnson"
          ],
          "interventions": [
            "Teclistamab",
            "Mezigdomide"
          ],
          "last_update": "2025-11-28",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07105059"
        },
        {
          "nct_id": "NCT07030517",
          "title": "An Open Label, Multicenter, Phase IV Study of Teclistamab to Evaluate Its Safety in Indian Participants With Relapsed and Refractory Multiple Myeloma Who Have Previously Received at Least 3 Prior Lines of Therapy Including an Immunomodulatory Agent, a Proteasome Inhibitor and an Anti-CD38 Antibody and Have Demonstrated Disease Progression on the Last Therapy",
          "overall_status": "RECRUITING",
          "phase": null,
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Johnson & Johnson Private Limited",
          "collaborators": [],
          "interventions": [
            "Teclistamab"
          ],
          "last_update": "2025-12-24",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07030517"
        },
        {
          "nct_id": "NCT04108195",
          "title": "A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Subjects With Multiple Myeloma",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Daratumumab",
            "Talquetamab",
            "Teclistamab",
            "Pomalidomide"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04108195"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok",
      "_ctgov_query_terms": [
        "TECVAYLI (teclistamab)",
        "teclistamab",
        "TECVAYLI"
      ]
    },
    {
      "asset": "TALVEY + TECVAYLI",
      "indication": "TIE NDMM in combination with DR",
      "phase": null,
      "trial_or_program": "MajesTEC-7",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT06285318",
          "title": "A Retrospective, Multicountry Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma Treated With T-cell Redirectors Outside of Clinical Trials",
          "overall_status": "RECRUITING",
          "phase": null,
          "conditions": [
            "Relapsed/Refractory Multiple Myeloma (RRMM)"
          ],
          "lead_sponsor": "Janssen-Cilag Ltd.",
          "collaborators": [],
          "interventions": [
            "Teclistamab",
            "Talquetamab"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06285318"
        },
        {
          "nct_id": "NCT06208150",
          "title": "A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants With Relapsed or Refractory Myeloma Who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Talquetamab",
            "Pomalidomide",
            "Teclistamab",
            "Elotuzumab",
            "Dexamethasone",
            "Bortezomib"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06208150"
        },
        {
          "nct_id": "NCT05972135",
          "title": "Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "SCRI Development Innovations, LLC",
          "collaborators": [
            "Johnson & Johnson"
          ],
          "interventions": [
            "Teclistamab",
            "Talquetamab",
            "Tocilizumab"
          ],
          "last_update": "2025-10-29",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05972135"
        },
        {
          "nct_id": "NCT07029776",
          "title": "A Phase 2 Study Exploring the Use of Bispecific Antibodies to Improve Progression Free Survival in Patients With High-Risk Newly Diagnosed Multiple Myeloma (MMulti-Immune HR)",
          "overall_status": "NOT_YET_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma (MM)"
          ],
          "lead_sponsor": "University of Arkansas",
          "collaborators": [
            "Janssen Research & Development, LLC"
          ],
          "interventions": [
            "teclistamab+daratumumab followed by talquetamab+daratumumab followed by duration treatment with daratumumab and lenalidomide extended/maintenance",
            "melphalan (MEL)-based hematopietic stem cell transplantation (HSCT) followed by drug therapy"
          ],
          "last_update": "2025-11-06",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07029776"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok",
      "_ctgov_query_terms": [
        "TALVEY + TECVAYLI"
      ]
    },
    {
      "asset": "TECVAYLI (teclistamab)",
      "indication": "Relapsed Refractory Multiple Myeloma CD38 exposed",
      "phase": null,
      "trial_or_program": "MajesTEC-9",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT05243797",
          "title": "Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation - MajesTEC-4",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "European Myeloma Network B.V.",
          "collaborators": [
            "Janssen Pharmaceutica"
          ],
          "interventions": [
            "Teclistamab",
            "Lenalidomide"
          ],
          "last_update": "2025-12-30",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05243797"
        },
        {
          "nct_id": "NCT06285318",
          "title": "A Retrospective, Multicountry Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma Treated With T-cell Redirectors Outside of Clinical Trials",
          "overall_status": "RECRUITING",
          "phase": null,
          "conditions": [
            "Relapsed/Refractory Multiple Myeloma (RRMM)"
          ],
          "lead_sponsor": "Janssen-Cilag Ltd.",
          "collaborators": [],
          "interventions": [
            "Teclistamab",
            "Talquetamab"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06285318"
        },
        {
          "nct_id": "NCT06251076",
          "title": "Outpatient-based Teclistamab Step-up Dosing in Patients With Relapsed/Refractory Multiple Myeloma: Process Development in Academic and Community Centres, and Evaluating Impact on Caregiver Burden",
          "overall_status": "RECRUITING",
          "phase": null,
          "conditions": [
            "Multiple Myeloma",
            "Relapsed Cancer",
            "Refractory Cancer"
          ],
          "lead_sponsor": "University Health Network, Toronto",
          "collaborators": [
            "Janssen Inc."
          ],
          "interventions": [
            "Teclistamab",
            "Tocilizumab"
          ],
          "last_update": "2025-12-10",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06251076"
        },
        {
          "nct_id": "NCT06208150",
          "title": "A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants With Relapsed or Refractory Myeloma Who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Talquetamab",
            "Pomalidomide",
            "Teclistamab",
            "Elotuzumab",
            "Dexamethasone",
            "Bortezomib"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06208150"
        },
        {
          "nct_id": "NCT07110844",
          "title": "A Phase 2 Clinical Trial of Teclistamab and Daratumumab in Previously Untreated AL Amyloidosis",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Amyloid Light-chain Amyloidosis"
          ],
          "lead_sponsor": "Suzanne Lentzsch, MD",
          "collaborators": [
            "Janssen Pharmaceuticals"
          ],
          "interventions": [
            "Teclistamab",
            "Daratumumab and Hyaluronidase-fihj"
          ],
          "last_update": "2025-11-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07110844"
        },
        {
          "nct_id": "NCT04696809",
          "title": "A Phase 1/2 Study of JNJ-64007957, a Humanized BCMA * CD3 Bispecific Antibody in Japanese Patients With Relapsed or Refractory Multiple Myeloma",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Hematologic Malignancies"
          ],
          "lead_sponsor": "Janssen Pharmaceutical K.K.",
          "collaborators": [],
          "interventions": [
            "Teclistamab"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04696809"
        },
        {
          "nct_id": "NCT04557098",
          "title": "A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Teclistamab, a Humanized BCMA x CD3 Bispecific Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Hematological Malignancies"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Teclistamab"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04557098"
        },
        {
          "nct_id": "NCT07105059",
          "title": "Teclistamab and Mezigdomide for Relapsed/Refractory Multiple Myeloma",
          "overall_status": "RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Memorial Sloan Kettering Cancer Center",
          "collaborators": [
            "Bristol-Myers Squibb",
            "Johnson & Johnson"
          ],
          "interventions": [
            "Teclistamab",
            "Mezigdomide"
          ],
          "last_update": "2025-11-28",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07105059"
        },
        {
          "nct_id": "NCT07030517",
          "title": "An Open Label, Multicenter, Phase IV Study of Teclistamab to Evaluate Its Safety in Indian Participants With Relapsed and Refractory Multiple Myeloma Who Have Previously Received at Least 3 Prior Lines of Therapy Including an Immunomodulatory Agent, a Proteasome Inhibitor and an Anti-CD38 Antibody and Have Demonstrated Disease Progression on the Last Therapy",
          "overall_status": "RECRUITING",
          "phase": null,
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Johnson & Johnson Private Limited",
          "collaborators": [],
          "interventions": [
            "Teclistamab"
          ],
          "last_update": "2025-12-24",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07030517"
        },
        {
          "nct_id": "NCT04108195",
          "title": "A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Subjects With Multiple Myeloma",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Daratumumab",
            "Talquetamab",
            "Teclistamab",
            "Pomalidomide"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04108195"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok",
      "_ctgov_query_terms": [
        "TECVAYLI (teclistamab)",
        "teclistamab",
        "TECVAYLI"
      ]
    },
    {
      "asset": "Bleximenib",
      "indication": "Relapsed Refractory Acute Myeloid Leukemia",
      "phase": null,
      "trial_or_program": "ALE1001",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT06852222",
          "title": "A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2A Rearrangements or NPM1 Mutations Who Are Ineligible for Intensive Chemotherapy",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Leukemia, Myeloid, Acute"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Bleximenib",
            "Venetoclax (VEN)",
            "Azacitidine (AZA)",
            "Placebo"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06852222"
        },
        {
          "nct_id": "NCT07295951",
          "title": "An Open-Label Study to Investigate the Absorption, Metabolism, And Excretion (AME) Of 14C-Bleximenib (JNJ-75276617) in Participants With Acute Leukemia",
          "overall_status": "RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Acute Lymphoblastic Leukemia",
            "Acute Leukemias",
            "Acute Myeloid Leukemia"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "14C-bleximenib",
            "bleximenib"
          ],
          "last_update": "2025-12-22",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07295951"
        },
        {
          "nct_id": "NCT05453903",
          "title": "A Phase 1b Study of Bleximenib in Combination With AML-Directed Therapies for Participants With Acute Myeloid Leukemia Harboring KMT2A or NPM1 Alterations",
          "overall_status": "RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Leukemia, Myeloid, Acute"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Bleximenib",
            "Venetoclax (VEN)",
            "Azacitidine (AZA)",
            "Cytarabine",
            "Daunorubicin or Idarubicin"
          ],
          "last_update": "2025-12-24",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05453903"
        },
        {
          "nct_id": "NCT04811560",
          "title": "A Phase 1/2, First-in-Human Study of the Menin-KMT2A (MLL1) Inhibitor Bleximenib in Participants With Acute Leukemia (cAMeLot-1)",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Acute Leukemias",
            "Acute Myeloid Leukemia",
            "Acute Lymphoblastic Leukemia"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Bleximenib"
          ],
          "last_update": "2025-12-10",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04811560"
        },
        {
          "nct_id": "NCT07223814",
          "title": "Bleximenib or Placebo in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for the Treatment of Patients With Newly Diagnosed KMT2A-rearranged or NPM1-mutant Acute Myeloid Leukemia Eligible for Intensive Chemotherapy: a Double-blind Phase 3 Study",
          "overall_status": "NOT_YET_RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Acute Myeloid Leukemia"
          ],
          "lead_sponsor": "Stichting Hemato-Oncologie voor Volwassenen Nederland",
          "collaborators": [
            "German-Austrian Acute Myeloid Leukemia Study Group"
          ],
          "interventions": [
            "Bleximenib",
            "Cytarabine",
            "Daunorubicin or Idarubicin",
            "Placebo"
          ],
          "last_update": "2025-11-03",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07223814"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok",
      "_ctgov_query_terms": [
        "Bleximenib"
      ]
    },
    {
      "asset": "JNJ-0683 (ARX788)",
      "indication": "Breast Cancer",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT04829604",
          "title": "A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "HER2 Positive Metastatic Breast Cancer"
          ],
          "lead_sponsor": "Ambrx, Inc.",
          "collaborators": [],
          "interventions": [
            "ARX788"
          ],
          "last_update": "2025-11-14",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04829604"
        },
        {
          "nct_id": "NCT06224673",
          "title": "Phase II Open-label Study of ARX788 (Anti-HER2 Antibody Drug Conjugate (ADC)) for Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer",
          "overall_status": "NOT_YET_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "HER2 Low Breast Carcinoma",
            "Triple Negative Breast Cancer",
            "Hormone-receptor-positive Breast Cancer",
            "Hormone Receptor Positive Breast Carcinoma"
          ],
          "lead_sponsor": "Laura Huppert, MD, BA",
          "collaborators": [
            "Ambrx, Inc."
          ],
          "interventions": [
            "ARX788",
            "Computed Tomography (CT)",
            "Biospecimen Collection",
            "Amiloride"
          ],
          "last_update": "2025-12-17",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06224673"
        },
        {
          "nct_id": "NCT06663748",
          "title": "Evaluate the Efficacy and Safety of ARX788 Given Every 6 Weeks in Patients with HER2-positive Advanced Breast Cancer",
          "overall_status": "NOT_YET_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "HER2-positive, Metastatic Breast Cancer"
          ],
          "lead_sponsor": "Henan Cancer Hospital",
          "collaborators": [],
          "interventions": [
            "ARX788"
          ],
          "last_update": "2024-10-29",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06663748"
        },
        {
          "nct_id": "NCT06578286",
          "title": "Evaluate the Efficacy and Safety of ARX788 in Patients With HER2-positive Advanced Breast Cancer Whose Disease Has Progressed Following T-DXd Therapy",
          "overall_status": "NOT_YET_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Breast Cancer"
          ],
          "lead_sponsor": "Fudan University",
          "collaborators": [],
          "interventions": [
            "ARX788"
          ],
          "last_update": "2024-08-29",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06578286"
        },
        {
          "nct_id": "NCT05018676",
          "title": "A Single-arm, Single-center Phase II Clinical Study of Recombinant Humanized Anti-HER2 Monoclonal Antibody-AS269 Conjugate (ARX788) in the Treatment of Unresectable and/or Metastatic Breast Cancer With Low Expression of HER2",
          "overall_status": "UNKNOWN",
          "phase": "Phase 2",
          "conditions": [
            "Breast Cancer With Low Expression of HER2"
          ],
          "lead_sponsor": "Fudan University",
          "collaborators": [],
          "interventions": [
            "ARX788"
          ],
          "last_update": "2022-04-25",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05018676"
        },
        {
          "nct_id": "NCT05041972",
          "title": "A Global Phase 2 Study to Evaluate the Efficacy and Safety of ARX788 for Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors",
          "overall_status": "WITHDRAWN",
          "phase": "Phase 2",
          "conditions": [
            "HER2 Mutation-Related Tumors",
            "HER2 Amplified Solid Tumors"
          ],
          "lead_sponsor": "Ambrx, Inc.",
          "collaborators": [],
          "interventions": [
            "ARX788"
          ],
          "last_update": "2022-09-13",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05041972"
        },
        {
          "nct_id": "NCT05018702",
          "title": "A Prospective, Single-arm, Single-center Phase II Clinical Study of Recombinant Humanized Anti-HER2 Monoclonal Antibody-AS269 Conjugate (ARX788) in the Treatment of HER2-positive Breast Cancer Patients With Brain Metastases",
          "overall_status": "UNKNOWN",
          "phase": "Phase 2",
          "conditions": [
            "HER2-positive, Metastatic Breast Cancer"
          ],
          "lead_sponsor": "Fudan University",
          "collaborators": [],
          "interventions": [
            "ARX788"
          ],
          "last_update": "2022-06-01",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05018702"
        },
        {
          "nct_id": "NCT02512237",
          "title": "A Phase 1, Multicenter, Open-label, Multiple Dose-escalation Study of ARX788, Intravenously Administered as a Single Agent in Subjects With Advanced Cancers With HER2 Expression",
          "overall_status": "TERMINATED",
          "phase": "Phase 1",
          "conditions": [
            "Breast Neoplasms",
            "Stomach Neoplasms"
          ],
          "lead_sponsor": "Zhejiang Medicine Co., Ltd.",
          "collaborators": [
            "Ambrx, Inc."
          ],
          "interventions": [
            "ARX788"
          ],
          "last_update": "2020-06-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT02512237"
        },
        {
          "nct_id": "NCT03255070",
          "title": "A Phase 1, Multicenter, Open-label, Multiple Dose-escalation and Expansion Study of ARX788, as Monotherapy in Advanced Solid Tumors With HER2 Expression",
          "overall_status": "COMPLETED",
          "phase": "Phase 1",
          "conditions": [
            "Breast Neoplasms",
            "Gastric Neoplasm",
            "Solid Tumors"
          ],
          "lead_sponsor": "Ambrx, Inc.",
          "collaborators": [],
          "interventions": [
            "ARX788"
          ],
          "last_update": "2024-02-01",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT03255070"
        },
        {
          "nct_id": "NCT05426486",
          "title": "A Randomized, Open Label, Multi-center Phase II-III Neoadjuvant Study Comparing the Efficacy and Safety of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) in Patients With HER2-positive Breast Cancer",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "HER2-positive Breast Cancer"
          ],
          "lead_sponsor": "Caigang Liu",
          "collaborators": [],
          "interventions": [
            "ARX788",
            "Pyrotinib maleate",
            "Trastuzumab",
            "Pertuzumab",
            "Docetaxel",
            "Carboplatin"
          ],
          "last_update": "2024-10-30",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05426486"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok",
      "_ctgov_query_terms": [
        "JNJ-0683 (ARX788)",
        "ARX788",
        "JNJ-0683"
      ]
    },
    {
      "asset": "JNJ-1900 (NBTXR3)",
      "indication": "Lung Cancer",
      "phase": null,
      "trial_or_program": null,
      "partner": "Nanobiotix",
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT04892173",
          "title": "A Phase 3 Study of NBTXR3 Activated by Investigator's Choice of Radiotherapy Alone or Radiotherapy in Combination With Cetuximab for Platinum-based Chemotherapy-Ineligible Elderly Patients With LA-HNSCC",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Locally Advanced Head and Neck Squamous Cell Carcinoma",
            "Aged"
          ],
          "lead_sponsor": "Johnson & Johnson Enterprise Innovation Inc.",
          "collaborators": [],
          "interventions": [
            "JNJ-90301900 (NBTXR3)",
            "Cetuximab",
            "Radiation Therapy"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04892173"
        },
        {
          "nct_id": "NCT04862455",
          "title": "Phase II Study of NBTXR3 Activated by Radiation and Combined With Pembrolizumab for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma With Limited PD-L1 Expression or Refractory to PD-1 Blockade",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Metastatic Head and Neck Squamous Cell Carcinoma",
            "Recurrent Head and Neck Squamous Cell Carcinoma"
          ],
          "lead_sponsor": "M.D. Anderson Cancer Center",
          "collaborators": [],
          "interventions": [
            "Hafnium Oxide-containing Nanoparticles NBTXR3",
            "Hypofractionated Radiation Therapy",
            "Pembrolizumab",
            "Stereotactic Body Radiation Therapy"
          ],
          "last_update": "2025-11-21",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04862455"
        },
        {
          "nct_id": "NCT07224152",
          "title": "NBTXR3 With Radiation Therapy Alone for Locally-advanced Non-small Cell Lung Cancer",
          "overall_status": "NOT_YET_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Locally-Advanced Non-Small Cell Lung Cancer"
          ],
          "lead_sponsor": "M.D. Anderson Cancer Center",
          "collaborators": [
            "Nanobiotix"
          ],
          "interventions": [
            "NBTXR3"
          ],
          "last_update": "2025-12-16",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07224152"
        },
        {
          "nct_id": "NCT07219212",
          "title": "A Study of JNJ-90301900 in Combination With Concurrent Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma",
          "overall_status": "RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Squamous Cell Carcinoma of Head and Neck"
          ],
          "lead_sponsor": "Johnson & Johnson Enterprise Innovation Inc.",
          "collaborators": [],
          "interventions": [
            "JNJ-90301900",
            "Cisplatin",
            "Intensity Modulated Radiation Therapy (IMRT)"
          ],
          "last_update": "2025-12-24",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07219212"
        },
        {
          "nct_id": "NCT02379845",
          "title": "A Multicenter Randomized, Open-Label Phase II/III Study, To Compare The Efficacy Of NBTXR3, Implanted As Intratumor Injection And Activated By Radiotherapy, Versus Radiotherapy Alone In Patients With Locally Advanced Soft Tissue Sarcoma Of The Extremity And Trunk Wall",
          "overall_status": "COMPLETED",
          "phase": "Phase 3",
          "conditions": [
            "Adult Soft Tissue Sarcoma"
          ],
          "lead_sponsor": "Nanobiotix",
          "collaborators": [
            "PharmaEngine"
          ],
          "interventions": [
            "NBTXR3",
            "Radiation therapy"
          ],
          "last_update": "2021-04-06",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT02379845"
        },
        {
          "nct_id": "NCT01433068",
          "title": "An Open-Label, Single Arm, Feasibility And Safety Phase I Study With NBTXR3 Intratumor Implantation (By Injection) And Activated By External Beam Radiation Therapy In Patients With Soft Tissue Sarcoma Of The Extremity And Trunk Wall",
          "overall_status": "COMPLETED",
          "phase": "Phase 1",
          "conditions": [
            "Adult Soft Tissue Sarcoma"
          ],
          "lead_sponsor": "Nanobiotix",
          "collaborators": [],
          "interventions": [
            "NBTXR3"
          ],
          "last_update": "2020-10-06",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT01433068"
        },
        {
          "nct_id": "NCT05039632",
          "title": "Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Advanced Malignant Solid Neoplasm",
            "Metastatic Malignant Neoplasm in the Liver",
            "Metastatic Malignant Neoplasm in the Lung",
            "Metastatic Malignant Solid Neoplasm"
          ],
          "lead_sponsor": "M.D. Anderson Cancer Center",
          "collaborators": [
            "National Cancer Institute (NCI)"
          ],
          "interventions": [
            "Hafnium Oxide-containing Nanoparticles NBTXR3",
            "Radiation Therapy",
            "Radiation Therapy"
          ],
          "last_update": "2025-11-06",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05039632"
        },
        {
          "nct_id": "NCT02805894",
          "title": "A Phase I-II Dose-escalation Study of NBTXR3 Activated by EBRT or EBRT With Brachytherapy in Patients With Newly Diagnosed Unfavorable Intermediate or High Risk Prostate Adenocarcinoma Treated With Androgen Deprivation",
          "overall_status": "TERMINATED",
          "phase": "Phase 2",
          "conditions": [
            "Prostate Cancer"
          ],
          "lead_sponsor": "Nanobiotix",
          "collaborators": [],
          "interventions": [
            "NBTXR3 activated by IMRT only",
            "NBTXR3 activated by Brachytherapy & IMRT"
          ],
          "last_update": "2021-05-10",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT02805894"
        },
        {
          "nct_id": "NCT03589339",
          "title": "A Phase I Dose Escalation / Dose Expansion Study of NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Radiotherapy",
            "Immunotherapy",
            "Microsatellite Instability-High Solid Malignant Tumour",
            "Metastasis From Malignant Tumor of Liver",
            "Squamous Cell Carcinoma of Head and Neck",
            "Metastasis From Malignant Tumor of Cervix",
            "Metastatic Renal Cell Carcinoma",
            "Metastasis From Malignant Melanoma of Skin (Disorder)",
            "Metastatic Triple-Negative Breast Carcinoma",
            "Metastatic NSCLC"
          ],
          "lead_sponsor": "Nanobiotix",
          "collaborators": [],
          "interventions": [
            "NBTXR3",
            "SABR",
            "Nivolumab",
            "Pembrolizumab"
          ],
          "last_update": "2025-10-24",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT03589339"
        },
        {
          "nct_id": "NCT02721056",
          "title": "A Phase I-II Study of NBTXR3 Activated by Sterostatic Body Radiation Therapy (SBRT) In the Treatment of Liver Cancers",
          "overall_status": "TERMINATED",
          "phase": "Phase 2",
          "conditions": [
            "Liver Cancer"
          ],
          "lead_sponsor": "Nanobiotix",
          "collaborators": [],
          "interventions": [
            "NBTXR3, IL or IA injection + SBRT"
          ],
          "last_update": "2021-05-10",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT02721056"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok",
      "_ctgov_query_terms": [
        "JNJ-1900 (NBTXR3)",
        "NBTXR3",
        "JNJ-1900"
      ]
    },
    {
      "asset": "TALVEY + TECVAYLI",
      "indication": "Relapsed Refractory Multiple Myeloma",
      "phase": null,
      "trial_or_program": "RedirecTT-1",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT06285318",
          "title": "A Retrospective, Multicountry Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma Treated With T-cell Redirectors Outside of Clinical Trials",
          "overall_status": "RECRUITING",
          "phase": null,
          "conditions": [
            "Relapsed/Refractory Multiple Myeloma (RRMM)"
          ],
          "lead_sponsor": "Janssen-Cilag Ltd.",
          "collaborators": [],
          "interventions": [
            "Teclistamab",
            "Talquetamab"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06285318"
        },
        {
          "nct_id": "NCT06208150",
          "title": "A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants With Relapsed or Refractory Myeloma Who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Talquetamab",
            "Pomalidomide",
            "Teclistamab",
            "Elotuzumab",
            "Dexamethasone",
            "Bortezomib"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06208150"
        },
        {
          "nct_id": "NCT05972135",
          "title": "Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "SCRI Development Innovations, LLC",
          "collaborators": [
            "Johnson & Johnson"
          ],
          "interventions": [
            "Teclistamab",
            "Talquetamab",
            "Tocilizumab"
          ],
          "last_update": "2025-10-29",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05972135"
        },
        {
          "nct_id": "NCT07029776",
          "title": "A Phase 2 Study Exploring the Use of Bispecific Antibodies to Improve Progression Free Survival in Patients With High-Risk Newly Diagnosed Multiple Myeloma (MMulti-Immune HR)",
          "overall_status": "NOT_YET_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma (MM)"
          ],
          "lead_sponsor": "University of Arkansas",
          "collaborators": [
            "Janssen Research & Development, LLC"
          ],
          "interventions": [
            "teclistamab+daratumumab followed by talquetamab+daratumumab followed by duration treatment with daratumumab and lenalidomide extended/maintenance",
            "melphalan (MEL)-based hematopietic stem cell transplantation (HSCT) followed by drug therapy"
          ],
          "last_update": "2025-11-06",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07029776"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok",
      "_ctgov_query_terms": [
        "TALVEY + TECVAYLI"
      ]
    },
    {
      "asset": "JNJ-0387",
      "indication": "Solid Tumors",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "JNJ-0387"
      ]
    },
    {
      "asset": "JNJ-0631 (ARX305)",
      "indication": "Renal Cancer",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "JNJ-0631 (ARX305)",
        "ARX305",
        "JNJ-0631"
      ]
    },
    {
      "asset": "JNJ-1493",
      "indication": "Hematological Malignancies",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "JNJ-1493"
      ]
    },
    {
      "asset": "JNJ-2638",
      "indication": "Gastrointestinal Cancer",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "JNJ-2638"
      ]
    },
    {
      "asset": "JNJ-2761",
      "indication": "Multiple Myeloma",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "JNJ-2761"
      ]
    },
    {
      "asset": "JNJ-3413",
      "indication": "Lymphoma",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "JNJ-3413"
      ]
    },
    {
      "asset": "JNJ-4496",
      "indication": "Hematological Malignancies",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "JNJ-4496"
      ]
    },
    {
      "asset": "JNJ-4680",
      "indication": "Lung Cancer",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "JNJ-4680"
      ]
    },
    {
      "asset": "JNJ-4681",
      "indication": "Hematological Malignancies",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "JNJ-4681"
      ]
    },
    {
      "asset": "JNJ-4916",
      "indication": "Lung Cancer",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "JNJ-4916"
      ]
    },
    {
      "asset": "JNJ-5322",
      "indication": "Multiple Myeloma",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "JNJ-5322"
      ]
    },
    {
      "asset": "JNJ-6420",
      "indication": "Prostate Cancer",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "JNJ-6420"
      ]
    },
    {
      "asset": "JNJ-7446",
      "indication": "Lung Cancer",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "JNJ-7446"
      ]
    },
    {
      "asset": "JNJ-8177 (ARX517)",
      "indication": "Prostate Cancer",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "JNJ-8177 (ARX517)",
        "ARX517",
        "JNJ-8177"
      ]
    },
    {
      "asset": "JNJ-8377",
      "indication": "Lymphoma",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "JNJ-8377"
      ]
    },
    {
      "asset": "JNJ-8543",
      "indication": "Hematological Malignancies",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "JNJ-8543"
      ]
    },
    {
      "asset": "JNJ-9401",
      "indication": "Prostate Cancer",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "JNJ-9401"
      ]
    },
    {
      "asset": "JNJ-9530",
      "indication": "Hematological Malignancies",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "JNJ-9530"
      ]
    },
    {
      "asset": "JNJ-9892",
      "indication": "Hematological Malignancies",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "JNJ-9892"
      ]
    },
    {
      "asset": "JNJ-9968",
      "indication": "Hematological Malignancies",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "JNJ-9968"
      ]
    },
    {
      "asset": "icotrokinra",
      "indication": "Psoriasis",
      "phase": null,
      "trial_or_program": "ICONIC",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "icotrokinra"
      ]
    },
    {
      "asset": "SIMPONI (golimumab)",
      "indication": "Pediatric Ulcerative Colitis",
      "phase": null,
      "trial_or_program": "PURSUIT 2",
      "partner": "Schering-Plough (Ireland) Company, a subsidiary of Merck & Co., Inc. and Mitsubishi Tanabe Pharma Corporation",
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "SIMPONI (golimumab)",
        "golimumab",
        "SIMPONI"
      ]
    },
    {
      "asset": "STELARA (ustekinumab)",
      "indication": "Pediatric Crohn's Disease",
      "phase": null,
      "trial_or_program": "UNITI JR",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "STELARA (ustekinumab)",
        "ustekinumab",
        "STELARA"
      ]
    },
    {
      "asset": "STELARA (ustekinumab)",
      "indication": "Pediatric Ulcerative Colitis",
      "phase": null,
      "trial_or_program": "UNIFI JR",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "STELARA (ustekinumab)",
        "ustekinumab",
        "STELARA"
      ]
    },
    {
      "asset": "TREMFYA (guselkumab)",
      "indication": "Pediatric Juvenile Psoriatic Arthritis",
      "phase": null,
      "trial_or_program": null,
      "partner": "MorphoSys AG",
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "TREMFYA (guselkumab)",
        "guselkumab",
        "TREMFYA"
      ]
    },
    {
      "asset": "TREMFYA (guselkumab)",
      "indication": "Pediatric Psoriasis",
      "phase": null,
      "trial_or_program": "PROTOSTAR",
      "partner": "MorphoSys AG",
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "TREMFYA (guselkumab)",
        "guselkumab",
        "TREMFYA"
      ]
    },
    {
      "asset": "TREMFYA (guselkumab)",
      "indication": "Psoriatic Arthritis Structural Damage",
      "phase": null,
      "trial_or_program": "APEX",
      "partner": "MorphoSys AG",
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "TREMFYA (guselkumab)",
        "guselkumab",
        "TREMFYA"
      ]
    },
    {
      "asset": "TREMFYA (guselkumab)",
      "indication": "Ulcerative Colitis Subcutaneous Induction",
      "phase": null,
      "trial_or_program": "ASTRO",
      "partner": "MorphoSys AG",
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "TREMFYA (guselkumab)",
        "guselkumab",
        "TREMFYA"
      ]
    },
    {
      "asset": "icotrokinra",
      "indication": "Psoriatic Arthritis",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "icotrokinra"
      ]
    },
    {
      "asset": "nipocalimab",
      "indication": "Warm Autoimmune Hemolytic Anemia",
      "phase": null,
      "trial_or_program": "ENERGY",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "nipocalimab"
      ]
    },
    {
      "asset": "nipocalimab",
      "indication": "Sjogren's Disease",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "nipocalimab"
      ]
    },
    {
      "asset": "nipocalimab",
      "indication": "Hemolytic Disease of the Fetus and Newborn",
      "phase": null,
      "trial_or_program": "AZALEA",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "nipocalimab"
      ]
    },
    {
      "asset": "nipocalimab",
      "indication": "Fetal and Neonatal Alloimmune Thrombocytopenia",
      "phase": null,
      "trial_or_program": "FREESIA",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "nipocalimab"
      ]
    },
    {
      "asset": "TREMFYA (guselkumab)",
      "indication": "Pediatric Ulcerative Colitis",
      "phase": null,
      "trial_or_program": "QUASAR JR",
      "partner": "MorphoSys AG",
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "TREMFYA (guselkumab)",
        "guselkumab",
        "TREMFYA"
      ]
    },
    {
      "asset": "icotrokinra",
      "indication": "Ulcerative Colitis",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "icotrokinra"
      ]
    },
    {
      "asset": "JNJ-4804 Co-antibody Therapy",
      "indication": "Ulcerative Colitis",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "JNJ-4804 Co-antibody Therapy"
      ]
    },
    {
      "asset": "JNJ-4804 Co-antibody Therapy",
      "indication": "Psoriatic Arthritis",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "JNJ-4804 Co-antibody Therapy"
      ]
    },
    {
      "asset": "JNJ-4804 Co-antibody Therapy",
      "indication": "Crohn's Disease",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "JNJ-4804 Co-antibody Therapy"
      ]
    },
    {
      "asset": "JNJ-5939",
      "indication": "Atopic Dermatitis",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "JNJ-5939"
      ]
    },
    {
      "asset": "nipocalimab",
      "indication": "Systemic Lupus Erythematosus",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "nipocalimab"
      ]
    },
    {
      "asset": "nipocalimab",
      "indication": "Idiopathic Inflammatory Myopathy",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "nipocalimab"
      ]
    },
    {
      "asset": "JNJ-5108",
      "indication": "Immunological Diseases",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "JNJ-5108"
      ]
    },
    {
      "asset": "JNJ-6848",
      "indication": "Immunological Diseases",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "JNJ-6848"
      ]
    },
    {
      "asset": "JNJ-7528",
      "indication": "Atopic Dermatitis",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "JNJ-7528"
      ]
    },
    {
      "asset": "CAPLYTA (lumateperone)",
      "indication": "Adjunctive Treatment for Major Depressive Disorder",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "CAPLYTA (lumateperone)",
        "lumateperone",
        "CAPLYTA"
      ]
    },
    {
      "asset": "IMAAVY (nipocalimab)",
      "indication": "Generalized Myasthenia Gravis",
      "phase": null,
      "trial_or_program": "Vivacity MG3",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "IMAAVY (nipocalimab)",
        "nipocalimab",
        "IMAAVY"
      ]
    },
    {
      "asset": "IMAAVY (nipocalimab)",
      "indication": "Generalized Myasthenia Gravis Pediatrics",
      "phase": null,
      "trial_or_program": "VIBRANCE MG",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "IMAAVY (nipocalimab)",
        "nipocalimab",
        "IMAAVY"
      ]
    },
    {
      "asset": "SPRAVATO (esketamine)",
      "indication": "Treatment Resistant Depression monotherapy",
      "phase": null,
      "trial_or_program": "TRD4005",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "SPRAVATO (esketamine)",
        "esketamine",
        "SPRAVATO"
      ]
    },
    {
      "asset": "CAPLYTA (lumateperone)",
      "indication": "Bipolar Mania",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "CAPLYTA (lumateperone)",
        "lumateperone",
        "CAPLYTA"
      ]
    },
    {
      "asset": "CAPLYTA (lumateperone)",
      "indication": "Pediatric Psychiatric Indications",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "CAPLYTA (lumateperone)",
        "lumateperone",
        "CAPLYTA"
      ]
    },
    {
      "asset": "nipocalimab",
      "indication": "Chronic Inflammatory Demyelinating Polyneuropathy",
      "phase": null,
      "trial_or_program": "ARISE",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "nipocalimab"
      ]
    },
    {
      "asset": "RPGR Gene Therapy",
      "indication": "Retinitis Pigmentosa",
      "phase": null,
      "trial_or_program": "LUMEOS",
      "partner": "UCL Business Plc",
      "notes": "AAV-RPGR",
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "RPGR Gene Therapy"
      ]
    },
    {
      "asset": "seltorexant",
      "indication": "Adjunctive Treatment for Major Depressive Disorder with Insomnia Symptoms",
      "phase": null,
      "trial_or_program": "OARS",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "seltorexant"
      ]
    },
    {
      "asset": "ITI-1284",
      "indication": "Generalized Anxiety Disorder",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "ITI-1284"
      ]
    },
    {
      "asset": "ITI-1284",
      "indication": "Alzheimer's Disease-Related Psychosis",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "ITI-1284"
      ]
    },
    {
      "asset": "ITI-1284",
      "indication": "Alzheimer's Disease-Related Agitation",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "ITI-1284"
      ]
    },
    {
      "asset": "JNJ-1887 sCD59",
      "indication": "Geographic Atrophy",
      "phase": null,
      "trial_or_program": null,
      "partner": "Hemera Biosciences",
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "JNJ-1887 sCD59"
      ]
    },
    {
      "asset": "JNJ-2056 (tau active immunotherapy)",
      "indication": "Alzheimer's Disease",
      "phase": null,
      "trial_or_program": "RETAIN",
      "partner": "AC Immune SA",
      "notes": "AC Immune ACI-35.030",
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "JNJ-2056 (tau active immunotherapy)",
        "tau active immunotherapy",
        "JNJ-2056"
      ]
    },
    {
      "asset": "JNJ-5120",
      "indication": "Major Depressive Disorder",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "JNJ-5120"
      ]
    },
    {
      "asset": "posdinemab",
      "indication": "Alzheimer's Disease",
      "phase": null,
      "trial_or_program": "AUTONOMY",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "posdinemab"
      ]
    },
    {
      "asset": "SPRAVATO (esketamine)",
      "indication": "Major Depressive Disorder with Suicidal Ideation Pediatrics",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "SPRAVATO (esketamine)",
        "esketamine",
        "SPRAVATO"
      ]
    },
    {
      "asset": "CABENUVA",
      "indication": "HIV Adolescents",
      "phase": null,
      "trial_or_program": null,
      "partner": "ViiV Healthcare",
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "CABENUVA"
      ]
    },
    {
      "asset": "UPTRAVI (selexipag)",
      "indication": "Pediatric Pulmonary Arterial Hypertension",
      "phase": null,
      "trial_or_program": "SALTO",
      "partner": "Nippon Shinyaku",
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "UPTRAVI (selexipag)",
        "selexipag",
        "UPTRAVI"
      ]
    },
    {
      "asset": "macitentan",
      "indication": "Pulmonary Arterial Hypertension 75mg",
      "phase": null,
      "trial_or_program": "UNISUS",
      "partner": "Nippon Shinyaku",
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "macitentan"
      ]
    },
    {
      "asset": "milvexian (Factor Xla)",
      "indication": "Secondary Stroke Prevention",
      "phase": null,
      "trial_or_program": null,
      "partner": "Bristol Myers Squibb",
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "milvexian (Factor Xla)",
        "Factor Xla",
        "milvexian"
      ]
    },
    {
      "asset": "milvexian (Factor Xla)",
      "indication": "Acute Coronary Syndrome",
      "phase": null,
      "trial_or_program": null,
      "partner": "Bristol Myers Squibb",
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "milvexian (Factor Xla)",
        "Factor Xla",
        "milvexian"
      ]
    },
    {
      "asset": "milvexian (Factor Xla)",
      "indication": "Atrial Fibrillation",
      "phase": null,
      "trial_or_program": null,
      "partner": "Bristol Myers Squibb",
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "milvexian (Factor Xla)",
        "Factor Xla",
        "milvexian"
      ]
    },
    {
      "asset": "SIRTURO",
      "indication": "Leprosy",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "SIRTURO"
      ]
    },
    {
      "asset": "SIRTURO",
      "indication": "Tuberculosis Long Acting",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none",
      "_ctgov_query_terms": [
        "SIRTURO"
      ]
    }
  ],
  "_meta": {
    "run_date_utc": "2026-01-08",
    "source_url": "https://s203.q4cdn.com/636242992/files/doc_financials/2025/q3/JNJ-Pipeline-3Q25.pdf",
    "input_text_sha256": "c8346bd17a91794d9b776b0953bb625a6580b4ee8d53710ed2d456500a7a481d",
    "ocr_max_pages": 12,
    "ocr_dpi": 220,
    "source_type": "jnj_q4cdn_auto",
    "stored_pdf_path": "sources/jnj/2026-01-08.pdf",
    "source_sha256": "7be7a71814f547e8772f826b14552f40244c9d6a9dd0548d8b79a85c3f1a9e04",
    "doc_unchanged": true,
    "doc_unchanged_note": "Source PDF SHA256 unchanged; reused prior snapshot to avoid extraction variability.",
    "extraction_ok": true,
    "ctgov": {
      "enabled": true,
      "queried_assets": [
        "AKEEGA (niraparib/abiraterone)",
        "DARZALEX (daratumumab)",
        "IMBRUVICA (ibrutinib)",
        "INLEXZO (gemcitabine intravesical system)",
        "RYBREVANT (amivantamab)",
        "Bleximenib",
        "CARVYKTI (Ciltacabtagene autoleucel)",
        "ERLEADA (apalutamide)",
        "JNJ-1900 (NBTXR3)",
        "pasritamig",
        "TALVEY + TECVAYLI",
        "TALVEY (talquetamab)",
        "TAR-210 (RIS/erdafitinib)",
        "TECVAYLI (teclistamab)",
        "JNJ-0683 (ARX788)",
        "JNJ-0387",
        "JNJ-0631 (ARX305)",
        "JNJ-1493",
        "JNJ-2638",
        "JNJ-2761",
        "JNJ-3413",
        "JNJ-4496",
        "JNJ-4680"
      ],
      "queries_executed": 51,
      "programs_total": 101,
      "programs_with_matches": 32,
      "phase_mismatches": 0,
      "phase_mismatch_examples": [],
      "sources_path": "sources/jnj/ctgov/2026-01-08",
      "api_base": "https://clinicaltrials.gov/api/v2"
    },
    "sec_edgar": {
      "enabled": true,
      "since_date": "2025-10-10",
      "forms": [
        "10-K",
        "10-Q",
        "8-K",
        "6-K",
        "20-F"
      ],
      "filings_considered": 0,
      "filings_with_events": 0,
      "sources_path": "sources/jnj/sec/2026-01-08",
      "deduped_accessions_count": 2
    },
    "press": {
      "enabled": true,
      "feed_url": "https://www.jnj.com/rss-feed/all",
      "links_scanned": 10,
      "new_releases_processed": 0,
      "releases_with_events": 0,
      "sources_path": "sources/jnj/press/2026-01-08"
    }
  }
}